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SUMMARY 
 
This is the 20
th
 annual statistical report of the National Cancer Registry.  The report summarises cancer incidence in Ireland 
for the period 1994 to 2013,  with particular emphasis on the most recent three years for which reliable data are available 
(2011-2013) , longer-term trends in incidence, and prevalence (the numbers of cancer patients still alive). Brief summaries of 
cancer mortality (2011-2012 data) and survival are also included. 
Incidence: new cases per year 
An average of 37,000 neoplasms was registered annually between 2011 and 2013 inclusive. Approximately 19% of these 
were non-invasive. Approximately 30,000 cases of invasive cancer, or 20,500 cases excluding non-melanoma skin cancer 
(NMSC), were registered annually. Incidence rates for all invasive cancers combined, excluding NMSC, were 28% higher for 
men than for women and cumulative lifetime risk (to age 75 years) remains approximately 1 in 3 for men and 1 in 4 for 
women.  
Incidence trends 
For males, the rate of diagnosis of invasive cancer (excluding NMSC) reached a plateau over the period of 2008-2013. This 
was probably due to the static incidence rate of prostate cancer since 2004, a consistent fall in the rate of lung and bladder 
cancer since 1994, and of leukaemia since 2004. Rates of invasive cancer (excluding NMSC) in females have increased 
significantly by about 1% annually since 1994, without evidence of a plateau. Population screening for breast and cervical 
cancer probably had some bearing on this as did the continuing upward trend in female lung cancer. For the first time, lung 
cancer has now marginally overtaken colorectal cancer as the 2
nd
 most common cancer diagnosed in females (average counts 
2011-2013). Lung cancer incidence fell by 1% annually in males but increased by >2% annually in females over the period 
1994-2013.  
For the first time, this report also explores the implications and feasibility of using the latest EUROSTAT population age 
weights (ESP 2013) as opposed to the 1976 weights previously used by the NCR and other European registries for age-
standardisation of cancer incidence rates.  Rates are calculated for all the main cancer sites, and annual rates and trends 
compared, using both population weights. In general, rates calculated using the new standard tended to be higher (because 
older populations are more heavily weighted) but for most cancers types this did not affect assessment of time-trends in 
incidence. 
Mortality: deaths from cancer 
Lung cancer was the leading cause of cancer death in both sexes, comprising 18% of cancer deaths in women and 23% of 
cancer deaths in men during the period 2011-2012. Deaths from lung, colorectal, breast and prostate cancers combined 
made up almost half of all deaths from cancer during this period. 
Cancer survival 
A full analysis of cancer survival is not included in this report, but net survival figures are presented for colorectal, cervical 
and female breast cancers. Age-standardised, five-year net survival for colorectal cancer patients improved from 57% to 61%, 
for breast cancer from 80% to 82% and for cervical cancer from 56% to 62% between diagnosis periods 2003-2007 and 2008-
2012. These improvements were generally also evident at regional level (HSE area of residence). 
Cancer prevalence 
For the diagnosis period 1994-2013 there were approximately 124,000 persons still alive at the end of 2013 after diagnosis 
with invasive cancer (excluding NMSC). In this 20-year prevalent population the most numerous cancer survivors were 
ranked as follows: 1) breast, 2) prostate, 3) colorectal and 4) melanoma of the skin.    
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1. INCIDENCE 2011-2013 
 
An average of approximately 37,000 cancers and other (non-invasive) tumours was registered per year between 2011 and 
2013 inclusive, representing an overall age-standardised incidence rate of 764 female cases and 795 male cases per 100,000 
per year (based on the 1976 European standard population; Table 1-1). Approximately 19% of these were non-invasive 
tumours (in situ carcinomas, tumours of uncertain behaviour and benign brain and CNS tumours) and 26% were invasive non-
melanoma skin cancers (NMSC, 9,512 cases per year). Invasive cancers as a whole averaged 30,000 per year during 2011-
2013, or an age-standardised rate of 546 female and 724 male cases per 100,000 per year. 
For all invasive cancers excluding NMSC, the figures most often quoted in international comparisons, approximately 20,500 
cases were registered annually, representing 68% of all registered cases and equivalent to an incidence rate of 384 cases per 
100,000 females and 490 cases per 100,000 males per year. This rate was 28% higher for men than for women (similar to 
previously published figures for Ireland), and cumulative lifetime risk (to age 75 years) remained approximately 1 in 3 for men 
and 1 in 4 for women. Further statistics by individual cancer type are summarised below and, for a longer list of sites, in 
Appendix I. 
 
Table 1-1. Annual average incidence of most common cancers: 2011-2013 
ICD10 site  CASES RATE**  
per 100,000 
% RISK to  
age 75 years 
% of all invasive cancers 
  females males total females males females males females males total 
C00-C96: all invasive cancers 13,726 16,240 29,966 546.0 723.8 35.05 44.40 100.0 100.0 100.0 
C00-C43, C45-C96 all invasive cancers, excluding NMSC 9,506 10,948 20,454 384.1 489.5 26.45 33.68 69.3 67.4 68.3 
C00-D48 all registered cancers 19,215 17,848 37,062 763.7 795.1 44.86 47.44       
D00-D48: all non-invasive cancers 5,488 1,608 7,096 217.7 71.3 15.11 5.46       
mouth & pharynx 122 280 403 5.1 12.7 0.41 1.12 0.9 1.7 1.3 
oesophagus 138 251 389 5.0 11.3 0.36 0.95 1.0 1.6 1.3 
stomach 192 341 532 7.1 15.1 0.50 1.18 1.4 2.1 1.8 
colorectum 1,019 1,441 2,460 39.0 64.0 3.01 4.96 7.4 8.9 8.2 
liver 75 167 243 2.8 7.4 0.21 0.58 0.6 1.0 0.8 
pancreas 238 259 496 8.7 11.5 0.62 0.89 1.7 1.6 1.7 
lung and trachea 1,027 1,292 2,318 40.3 57.3 3.29 4.45 7.5 8.0 7.7 
melanoma of skin 491 422 913 19.8 18.7 1.56 1.46 3.6 2.6 3.1 
other malignant neoplasms of skin (NMSC) 4,220 5,292 9,512 161.9 234.4 11.69 16.18 30.7 32.6 31.7 
breast 2,883 34 2,917 122.6 1.5 9.61 0.12 21.0 0.2 9.7 
cervix 295   295 12.4   0.96   2.2   1.0 
corpus uteri 435   435 18.6   1.64   3.2   1.5 
ovary 361   361 14.8   1.19   2.6   1.2 
other gynaecological cancers† 102   102 4.1   0.31   0.8   0.3 
prostate                        3,400 3,400  154.3 0.00 13.77   20.9 11.4 
testis   167 167   7.0   0.50   1.0 0.6 
kidney 197 373 570 8.0 16.7 0.68 1.35 1.4 2.3 1.9 
bladder 135 306 440 4.9 13.5 0.33 0.95 1.0 1.9 1.5 
all brain & CNS tumours 311 285 597 12.9 12.7 1.01 1.02       
brain and CNS: malignant  156 199 355 6.4 8.8 0.51 0.73 1.1 1.2 1.2 
brain & CNS: benign  120 55 175 4.9 2.4 0.40 0.20       
brain & CNS: uncertain  35 32 67 1.5 1.4 0.10 0.10       
thyroid 205 69 275 8.6 3.0 0.68 0.25 1.5 0.4 0.9 
lymphoma (total) 412 480 892 16.8 21.4 1.38 1.67 3.0 3.0 3.0 
Hodgkin lymphoma 60 75 135 2.6 3.3 0.20 0.25 0.4 0.5 0.5 
non-Hodgkin lymphoma 352 406 757 14.2 18.1 1.18 1.42 2.6 2.5 2.5 
multiple myeloma  96 153 249 3.6 6.8 0.26 0.51 0.7 0.9 0.8 
leukaemia (total) 190 289 479 7.6 12.9 0.59 0.93 1.4 1.8 1.6 
other invasive tumours (not listed ‡) 737 1,025 1,762         5.3 6.3 5.8 
           
* invasive cancer included all tumours classified as behaviour 3 in ICD-O-3 classification (including some neoplasms previously classified as 
uncertain behaviour) [1] 
**rates are standardised to the 1976 European standard population (ESP) [2] – see Appendix I for rates standardised to the 2013 ESP 
† vulva, vagina, uterus (NOS) and placenta 
‡ see Appendix I for further site-specific statistics 
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Figure 1-1. Relative frequency of the most common invasive cancers (including non-melanoma skin cancer) diagnosed 
during 2011-2013 
FEMALES MALES 
  
  
 
Table 1-2. Proportions and ranks of the most commonly diagnosed invasive cancers (excluding NMSC): 2011-2013 
 FEMALES  MALES  ALL  
 % rank % rank % rank 
C00-C43, C45-C96 all invasive cancers, excluding NMSC 100.0%  100.0%  100.0%  
prostate   31.1% 1 16.6% 1 
breast 30.3% 1   14.3% 2 
colorectal 10.7% 3 13.2% 2 12.0% 3 
lung 10.8% 2 11.8% 3 11.3% 4 
melanoma of skin 5.2% 4 3.9% 5 4.5% 5 
lymphoma 4.3% 6 4.4% 4 4.4% 6 
kidney 2.1% 11 3.4% 6 2.8% 7 
stomach 2.0% 12 3.1% 7 2.6% 8 
pancreas 2.5% 9 2.4% 11 2.4% 9 
leukaemia 2.0% 13 2.6% 9 2.3% 10 
bladder 1.4% 16 2.8% 8 2.2% 11 
corpus uteri 4.6% 5   2.1% 12 
mouth & pharynx 1.3% 17 2.6% 10 2.0% 13 
oesophagus 1.5% 15 2.3% 12 1.9% 14 
ovary 3.8% 7   1.8% 15 
brain & CNS 1.6% 14 1.8% 13 1.7% 16 
cervix 3.1% 8   1.4% 17 
thyroid 2.2% 10 0.6% 17 1.3% 18 
multiple myeloma 1.0% 18 1.4% 16 1.2% 19 
liver 0.8% 19 1.5% 15 1.2% 20 
testis   1.5% 14 0.8% 21 
other sites not listed 8.5%  9.5%  9.0%  
 
NMSC was the most common invasive cancer, representing 31% and 33% of all cases in females and males respectively 
(Figure 1-1). If NMSC was excluded, prostate and female breast cancer were the most commonly diagnosed cancers overall, 
and each comprised almost one-third of all cancers in men and women respectively (Table 1-2). Colorectal and lung cancer 
were the 2
nd
 and 3
rd
 most common cancers in males, but for the first time lung cancer has moved from 3
rd
 place to 2
nd
 place 
ahead of colorectal cancer in females. Otherwise, there was little change observed in the relative frequency of individual 
cancer types from the last annual report (which presented 2010-2012 averages) [3]. 
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Comparison of incidence rates standardised using the ‘old’ (1976) and ‘new’ (2013) European standard populations 
The age-standardised (ASR) rate for any specified disease is the annual rate of newly diagnosed cases (or deaths) in a given 
population (and year), expressed per 100,000 persons, weighted by the age-structure of a defined ‘standard’ population in 
order  to allow meaningful comparisons between different European countries or over time.  
By convention for European cancer registries, age-standardised rates for incidence and mortality are typically weighted by 
the European standard population (ESP) as defined in 1976 [2]. However, in this report (Figures 1-2, 1-3 and Appendix I) the 
NCR has, for the first time, also presented rates weighted by the 2013 ESP proposed by EUROSTAT to more accurately reflect 
the demographic age shift in the European population since 1976 [4]. The 2013 ESP is a better reflection of the current 
population structure than the ESP of 1976, and gives older ages a greater weight than the 1976 ESP (see Methods section) 
In general, incidence rates for cancer sites during 2011-2013 tended to be higher when calculated using the more recent age 
weights (ESP 2013). This is more apparent for cancer sites with older median age of incidence (Figure 1-2), e.g. bladder 
cancer (74 years), which tended to have a much greater relative difference in rates between the ESP 1976 and ESP 2013 
calculations than cancers with a lower median age at diagnosis, e.g. Hodgkin lymphoma (38 years) (Figures 1-3, 1-4).  
For the immediate future, the NCR will continue to publish incidence and mortality rates using the 1976 standard population 
but with rates also provided based on the 2013 standard, both in published reports and (when the necessary programming 
has been completed) on the NCR website.  
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Figure 1-2.  
Comparison of incidence rates calculated using 1976 and 2013 European standard population (ESP) weights: average annual age-standardised rates for 2011-2013 
MALES FEMALES 
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Figure 1-3.  
Relative difference between age standardised rate calculated with ESP1976 and ESP2013 
 Figure 1-4.  
Comparison of age-specific % breakdown of cases 2011-2013: 
bladder cancer and Hodgkin lymphoma, both sexes combined 
 
 
 
Median age for both sexes combined are shown in brackets 
*relative difference % =[ (rate calculated using ESP2013/rate  calculated using ESP1976) -1]*100 
Note: testis and in situ cervix show small negative values (ESP2013 rate < ESP1976 rate) 
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2. MORTALITY 2011-2012 
 
Cancer continues to be the second most common cause of death in Ireland, after diseases of the circulatory system, and an 
annual average of 8,827 deaths from cancer or other neoplasms occurred during the period 2011-2012. This represented 
about 30% of all deaths for the period and an age-standardised mortality rate of 153 deaths per 100,000 females and 211 
deaths per 100,000 males per year (Table 2-1). All-cancer mortality rates were approximately 37% higher in men than in 
women. The lifetime risk (to age 75 year) of dying from cancer was approximately 1 in 10 for women and 1 in 8 for men.  
 
Some deaths were attributed to non-invasive tumours (‘D00-D48: All non-invasive neoplasm deaths’, Table 2-1). These mostly 
comprise two groups: 1) benign and uncertain-behaviour neoplasms of the brain and CNS, which can be as fatal as malignant 
brain tumours; 2) some blood cancers such as polycythaemia vera, myelodysplastic syndromes and related neoplasms of 
uncertain or unknown behaviour, previously classed as non-malignant (in the ICD10 coding scheme still used for official 
mortality statistics in Ireland) but now classed as malignant for purposes of cancer incidence reporting. 
 
A more detailed breakdown of mortality statistics by cancer site is given below and, in more detail, in Appendix II. 
 
Table 2-1. Average annual number of deaths from cancer: 2011-2012 
 DEATHS RATE* 
per 100,000 
% RISK to 
 age 75 Y 
% of all registered  
cancer deaths 
 females males total females males females males females males total 
C00-D48 all registered cancer/neoplasm deaths 4,135 4,692 8,827 152.9 211.1 10.26 12.9 100.0 100.0 100.0 
C00-C96: All invasive cancer deaths 4,038 4,581 8,619 149.9 206.1 10.12 12.7 97.7 97.6 97.7 
C00-C43, C45-C96 all invasive cancer deaths, excluding NMSC 4,012 4,539 8,551 149.1 204.1 10.1 12.6 97.0 96.7 96.9 
D00-D48: All non-invasive neoplasm deaths 97 111 208 3.1 5.0 0.15 0.22 2.3 2.4 2.4 
mouth & pharynx 50 114 164 1.9 5.2 0.14 0.44 1.2 2.4 1.9 
oesophagus 137 231 368 4.8 10.5 0.32 0.81 3.3 4.9 4.2 
stomach 120 201 320 4.1 9.0 0.25 0.6 2.9 4.3 3.6 
colorectal 409 591 1,000 14.3 26.5 0.91 1.73 9.9 12.6 11.3 
liver 106 143 249 3.8 6.5 0.25 0.49 2.6 3.1 2.8 
pancreas 226 251 477 8.2 11.3 0.55 0.78 5.5 5.4 5.4 
lung 745 1,081 1,826 28.4 48.5 2.14 3.53 18.0 23.0 20.7 
non-melanoma skin cancer 27 42 69 0.8 1.9 0.02 0.11 0.7 0.9 0.8 
melanoma of skin 65 84 148 2.4 3.7 0.16 0.26 1.6 1.8 1.7 
breast 690 8 698 26.7 0.4 1.99 0.03 16.7 0.2 7.9 
cervix 96  96 4.1  0.32  2.3  1.1 
corpus uteri 78   78 2.9   0.22   1.9   0.9 
ovary 277  277 10.9  0.83  6.7  3.1 
other gynaecological cancer deaths† 57   57 2.0   0.14   1.4   0.6 
prostate  541 541  24.4  1.01  11.5 6.1 
testis   8 8   0.3   0.03   0.2 0.1 
kidney 59 134 193 2.2 6.1 0.17 0.44 1.4 2.9 2.2 
bladder 77 138 215 2.4 6.2 0.11 0.31 1.9 2.9 2.4 
all brain & CNS tumours 133 179 312 5.2 8.0 0.43 0.65 3.2 3.8 3.5 
brain and CNS: malignant  111 160 271 4.5 7.1 0.37 0.59 2.7 3.4 3.1 
brain & CNS: benign  10 4 14 0.3 0.2 0.02 0.01 0.2 0.1 0.2 
brain & CNS: uncertain  13 16 28 0.4 0.7 0.04 0.05 0.3 0.3 0.3 
thyroid  18 10 27 0.7 0.4 0.05 0.04 0.4 0.2 0.3 
lymphoma 142 156 298 5.2 6.9 0.38 0.4 3.4 3.3 3.4 
Hodgkin lymphoma 14 11 25 0.5 0.4 0.04 0.03 0.3 0.2 0.3 
non-Hodgkin lymphoma 128 146 273 4.7 6.5 0.34 0.37 3.1 3.1 3.1 
multiple myeloma 74 92 166 2.5 4.1 0.14 0.26 1.8 2.0 1.9 
leukaemia 101 158 259 3.6 7.0 0.23 0.4 2.4 3.4 2.9 
other cancer deaths‡ 448 530 981     10.8 11.3 11.1 
*rates are standardised to the 1976 European standard population [2] 
†vulva, vagina, unspecified female genital, uterus (NOS), placenta 
‡see Appendix II for further site-specific mortality data 
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Figure 2-1. Relative frequency for the cancer deaths: 2011-2012 
FEMALES MALES 
  
Brain & CNS: includes malignant, benign and uncertain behaviours 
 
Table 2-2. Proportion and rank of the most common cancers deaths, by sex: 2011-2012 
 FEMALES  MALES  ALL  
 % rank % rank % rank 
C00-D48 all registered cancer/neoplasm deaths 100.0%  100.0%  100.0%  
lung 18.0% 1 23.0% 1 20.7% 1 
colorectal 9.9% 3 12.6% 2 11.3% 2 
breast 16.7% 2   7.9% 3 
prostate   11.5% 3 6.1% 4 
pancreas 5.5% 5 5.3% 4 5.4% 5 
oesophagus 3.3% 7 4.9% 5 4.2% 6 
stomach 2.9% 9 4.3% 6 3.6% 7 
all brain & CNS tumours‡ 3.2% 8 3.8% 7 3.5% 8 
lymphoma 3.4% 6 3.3% 9 3.4% 9 
ovary 6.7% 4   3.1% 10 
leukaemia 2.4% 11 3.4% 8 2.9% 11 
liver 2.6% 10 3.0% 10 2.8% 12 
bladder 1.9% 14 2.9% 11 2.4% 13 
kidney 1.4% 17 2.9% 12 2.2% 14 
multiple myeloma 1.8% 15 2.0% 14 1.9% 15 
mouth & pharynx 1.2% 19 2.4% 13 1.9% 16 
melanoma of skin 1.6% 16 1.8% 15 1.7% 17 
cervix 2.3% 12   1.1% 18 
corpus uteri 1.9% 13   0.9% 19 
non-melanoma skin cancer 0.7% 20 0.9% 16 0.8% 20 
other gynaecological cancer deaths† 1.4% 18   0.6% 21 
thyroid  0.4% 21 0.2% 17 0.3% 22 
testis   0.2% 18 0.1% 23 
other cancer deaths‡ 10.8%  11.3%  11.1%  
‡ Brain & CNS: includes malignant, benign and uncertain behaviours 
† vulva, vagina, placenta and uterus NOS 
 
Lung cancer was the leading cause of cancer death in both sexes, averaging 1,826 deaths per year or 18% of cancer deaths in 
women and 23% of cancer deaths in men during the period 2011-2012 (Figure 2-1). Deaths from lung, colorectal, breast and 
prostate cancers combined made up almost half of all deaths from cancer during this period. Deaths from cancers of the 
ovary and pancreas in females, and from cancers of the pancreas, oesophagus and stomach in males, made up 12% and 15% 
respectively of all cancer deaths. These high-fatality cancers ranked as the 4
th
 and 5
th
 most common causes of cancer death in 
women and 4
th
 to 6
th
 most common in men (Table 2-2), much higher than their incidence rankings (Table 1-2).  
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3. TRENDS IN INCIDENCE 1994-2013 
 
In previous NCR reports, cancer incidence trends have been assessed using rates age-standardised to the 1976 European 
standard population (ESP). For comparison, trends have also been assessed in this report using rates standardised to the 
2013 ESP. In section 1 it was noted that rates calculated using the 2013 ESP were generally higher than rates calculated using 
the 1976 ESP, reflecting the greater weighting given to older populations by the 2013 ESP. This raises an important question 
as to whether calculated trends differ if based on different population weights (1976 and 2013 ESP).   
Annual percentage changes (APC) in incidence over time were fitted using Joinpoint regression applied to annual age-
standardised rates and their standard errors for the period 1994-2013 [5][6].  
In interpreting the trends reported below, possible changes in diagnostic activity (e.g. introduction or expansion of screening, 
improvements in diagnosis methods) or in coding practices should be borne in mind, as well as possible changes in the true 
underlying risk of the cancers involved (reflecting changes over time in risk factors). 
 
Figure 3-1. Trend in incidence by sex: C00-C43, C45-C96 All invasive cancers, excluding NMSC 
 
 
APC‡: annual percentage change over the ‘from-to’ period & 95% confidence 
interval (95%CI) of APC  
 
trend†: ↑=significant increase, ↓=significant decrease, ↔=no change, at the 
95% level 
 MALE FEMALE 
 
from to APC‡ 95%CI trend† from to APC‡ 95%CI trend† 
ESP 1976 1994 2008 1.4 1.1 1.8 ↑ 1994 2013 1.0 0.8 1.2 ↑ 
ESP 1976 2008 2013 -0.3 -1.6 1.1 ↔ 
             
ESP2013 1994 2008 1.3 0.9 1.6 ↑ 1994 2013 0.9 0.8 1.1 ↑ 
ESP2013 2008 2013 -1.0 -2.3 0.4 ↔       
 
The incidence rate of invasive cancers excluding NMSC increased significantly by >1% annually in males until 2008, then the 
trend became static between 2008 and 2013, with some evidence for the beginning of a downward trend (Figure 3-1). The 
rate increased by 1% per annum in females through the period 1994-2013. The conspicuous levelling off in the rate of 
invasive cancers in males probably reflects, in part, a levelling off in prostate cancer diagnoses since 2004 (before which 
diagnoses increased rapidly) and an ongoing fall in the rate of male lung cancer. In contrast, increases in female lung cancer 
rates and increased detection of breast cancer through the BreastCheck screening programme probably contributed to the 
sustained increase in overall cancer rates for women. Bladder cancers have also decreased in both sexes over the same 
period, but more so in males, and leukaemia rates in males have also fallen since 2004. Calculated trends were broadly 
similar whether based on the 1976 or the 2013 ESP, although the 2013 ESP figures suggested a more marked recent decline 
in male incidence rates. 
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Figure 3-2. Trend in incidence by sex: C00-96 All invasive cancers  
 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 1999 0.1 -1.5 1.8 ↔ 1994 2013 1.2 1.0 1.4 ↑ 
ESP 1976 1999 2013 1.5 1.2 1.8 ↑ 
      
             
ESP 2013 1994 2013 1.1 0.9 1.3 ↑ 1994 2013 1.2 1.0 1.4 ↑ 
For all invasive cancers combined, the trend in females (1.2% annual increase during 1994-2013) was the same regardless of 
which population standard was used. For males there was a 1.1% annual increase over the period 1994-2013 using the 
ESP2013 population weight; however, using the ESP1976 standard, Joinpoint suggested a static trend until 1999, after which 
the rate increased by 1.5% annually (Figure 3-2). However, the patterns shown by the actual data points, for both males and 
females, are quite similar between the two standards for this all-cancer grouping, thus apparent differences in trends for 
males depending on which population standard is used should be interpreted with caution. 
Unlike the previous figure (Figure 3-1), which excluded non-melanoma skin cancers, there was no evidence of a plateau from 
2008 in males when NMSCs were included. This difference reflects the marked increase in NMSC in males from 2001 (by c.3% 
annually - see Figure 3-12).  
 
Figure 3-3. Trend in incidence by sex: D00-48 All non-invasive neoplasms  
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 6.8 6.2 7.4 ↑ 1994 2013 5.2 4.3 6.1 ↑ 
             
ESP 2013 1994 2013 7.2 6.6 7.8 ↑ 1994 2013 5.1 4.3 5.9 ↑ 
 
  
Figure 3-3 shows the substantially higher rate of incidence of non-invasive tumours in females compared to males, largely 
accounted for by in situ cervix and breast tumours which together comprise over 50% all non-invasive tumours regardless of 
sex (Appendix I). The rate of non-invasive tumours in females increased at 5% annually since 1994, latterly reflecting (at least 
in part) the implementation of the national breast and cervical screening programmes. The increased rate in males (by 7% 
annually) since 1994 was due in part to increases in patients presenting with in situ skin cancers since 2000. Trends were 
broadly similar for both sexes regardless of which population standard was used.  
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Figure 3-4. Trend in incidence by sex: C01-14 Cancer of mouth & pharynx 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2001 -4.4 -6.4 -2.2 ↓ 1994 2013 2.4 1.4 3.4 ↑ 
ESP 1976 2001 2013 2.8 1.9 3.7 ↑ 
      
             
ESP2013 1994 2001 -4.3 -6.8 -1.8 ↓ 1994 2013 1.9 0.8 2.9 ↑ 
ESP2013 2001 2013 2.4 1.3 3.4 ↑       
 
The incidence rate of oral and pharyngeal cancer increased by 2-3% annually for males from 2001 onwards (following an 
earlier decline by c.4% annually) and by c.2% annually for females throughout 1994-2013 (Figure 3-4). The trends were quite 
similar regardless of the population standard used (1976 or 2013 ESP). 
 
Figure 3-5. Trend in incidence by sex: C15 Oesophageal cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 -0.1 -0.7 0.6 ↔ 1994 2013 -1.1 -1.6 -0.5 ↓ 
             
ESP 2013 1994 2013 0.0 -0.7 0.7 ↔ 1994 2013 -1.0 -1.5 -0.4 ↓ 
 
There was no significant change in the annual incidence rate of oesophageal cancer in males, but the rate in females fell by 
1% annually during 1994-2013 (Figure 3-5). Trends were similar regardless of the choice of ESP (1976 or 2013). 
 
Figure 3-6. Trend in incidence by sex: C16 Stomach cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2002 -2.9 -4.5 -1.4 ↓ 1994 2013 -1.5 -2.0 -1.0 ↓ 
ESP 1976 2002 2013 -0.6 -1.5 0.3 ↔ 
      
             
ESP 2013 1994 2003 -3.1 -4.5 -1.6 ↓ 1994 2013 -1.5 -2.0 -1.1 ↓ 
ESP 2013 2003 2008 1.0 -4.0 6.2 ↔       
ESP 2013 2008 2013 -2.2 -5.5 1.2 ↔       
 
The incidence rate of stomach cancer in males declined significantly by c.3% annually up to 2002, before slowing (a non-
significant <1% annual decrease) during 2002-2013, based on rates calculated using the 1976 ESP (Figure 3-6). Use of the 
2013 ESP resulted in an extra break-point at 2008, but the post-2002 trends were again not statistically significant. In 
females, the incidence rate declined more steadily, by c1.5% annually during 1994-2013, regardless of which ESP was used.  
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Figure 3-7. Trend in incidence by sex: C18-20 Colorectal cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 0.1 -0.2 0.3 ↔ 1994 2013 0.0 -0.3 0.4 ↔ 
             
ESP 2013 1994 2008 0.6 0.2 0.9 ↑ 1994 2013 0.0 -0.2 0.4 ↔ 
ESP 2013 2008 2013 -1.0 -2.4 0.4 ↔       
 
The incidence rate of colorectal cancer in males and females did not change significantly during 1994-2013 when using the 
1976 ESP (Figure 3-7).  However rates calculated using the 2013 ESP increased by 0.6% annually in males from 1994 to 2008, 
followed by a non-significant trend (apparent decline). For females, trends were the same regardless of the population 
standard used. 
 
Figure 3-8. Trend in incidence by sex: C22 Liver cancer (including intrahepatic bile ducts) 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 6.4 5.4 7.4 ↑ 1994 2013 5.3 3.6 7.0 ↑ 
             
ESP 2013 1994 2013 6.5 5.5 7.4 ↑ 1994 2013 5.6 3.9 7.3 ↑ 
 
Rates of primary invasive liver increased by c.6.5% annually in males and c.5.5% in females during the period 1994-2013, 
regardless of which population standard was used (Figure 3-8). 
 
Figure 3-9. Trend in incidence by sex: C25 Pancreatic cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 0.5 -0.2 1.3 ↔ 1994 2013 0.4 -0.3 1.1 ↔ 
             
ESP 2013 1994 2013 0.4 -0.4 1.1 ↔ 1994 2013 0.4 -0.2 1.0 ↔ 
 
Incidence trends for pancreatic cancer suggest slight but non-significant increases, by c.0.5% annually, in both males and 
females (Figure 3-9). The trend was similar regardless of the choice of standard population (1976 or 2013 ESP).  
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Figure 3-10. Trend in incidence by sex: C33-34 Lung & tracheal cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 -0.8 -1.0 -0.5 ↓ 1994 2013 2.3 2.1 2.5 ↑ 
             
ESP 2013 1994 2013 -0.5 -0.7 -0.3 ↓ 1994 2013 2.3 2.1 2.6 ↑ 
 
The incidence rate of lung cancer declined steadily in males by almost 1% annually during 1994-2013 (slightly less if based on 
the 2013 ESP), whereas in females it increased significantly by over 2% annually over the same period (Figure 3-10). In both 
sexes, the trend was the similar regardless of the choice of standard population (1976 or 2013 ESP). 
 
Figure 3-11. Trend in incidence by sex: C43 Melanoma of skin 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 4.9 4.2 5.6 ↑ 1994 2013 2.6 2.0 3.2 ↑ 
             
ESP 2013 1994 2013 5.2 4.5 5.9 ↑ 1994 2013 2.9 2.3 3.5 ↑ 
 
For melanoma skin cancer, the rate of incidence in females increased by almost 3% annually during the period 1994-2012, 
and in males by c.5% annually over the same period. Trends were similar regardless of the choice of ESP (1976 or 2013). 
 
Figure 3-12. Trend in incidence by sex: C44 Non-melanoma skin cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2001 -1.8 -2.9 -0.7 ↓ 1994 2000 -0.9 -2.7 0.9 ↔ 
ESP 1976 2001 2013 3.1 2.7 3.6 ↑ 2000 2013 2.6 2.1 3.0 ↑ 
             
ESP 2013 1994 2001 -1.8 -2.8 -0.8 ↓ 1994 2001 -0.4 -1.9 1.1 ↔ 
ESP 2013 2001 2013 3.3 2.9 3.6 ↑ 2001 2013 2.7 2.1 3.2 ↑ 
 
Incidence rates of non-melanoma skin cancer have increased by c.3% annually since 2000 or 2001 in both males and females 
(Figure 3-12), following a period of more stable or declining rates. Trends were similar regardless of the choice of ESP (1976 
or 2013). 
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Figure 3-13. Trend in incidence by sex: C50 Breast cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 4.0 2.0 6.0 ↑ 1994 2013 1.5 1.1 1.9 ↑ 
             
ESP 2013 1994 2013 4.2 2.3 6.2 ↑ 1994 2013 1.6 1.2 1.9 ↑ 
 
The incidence rate for female breast cancer increased significantly by c.1.5% annually during the period 1994-2013 (Figure 3-
13). In large part, the incidence trend for malignant breast cancer probably reflects the introduction of the national breast 
screening program (BreastCheck) in the eastern half of the country from 2000 and the rest of the country by 2007. This is 
evident from the two peaks in incidence which followed the two roll-out phases.  Perhaps surprisingly, rates of breast cancer 
have risen more steeply among males (Figure 3-13), but based on much smaller numbers of cases annually. Trends were 
similar regardless of the choice of ESP (1976 or 2013). 
 
Figure 3-14. Trend in incidence: C53 Cervical cancer 
 
 
 FEMALE 
 
from to APC 95%CI trend 
ESP 1976 1994 2013 1.6 0.5 2.6 ↑ 
       
ESP 2013 1994 2013 1.5 0.4 2.5 ↑ 
 
The incidence rate for invasive cervical cancer increased by c.1.5% annually during 1994-2013 (Figure 3-14). Screening activity 
may have had some bearing on the upward trend in rates, and the increased rate we are seeing now may (in part) reflect 
increased or earlier detection of invasive cases. Increased detection of in situ carcinomas of the cervix through screening (see 
below) should, in theory, lead to a reduction in incidence of invasive cases, but it may be too soon yet to see this effect, and 
the suggestion in the trend graph of a reduction from 2009 onwards may be just a chance effect (reflecting low numbers of 
cases). The actual rates themselves and the trend were very similar regardless of choice of ESP (1976 or 2013). 
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Figure 3-15. Trend in incidence: D06 Carcinoma in situ of cervix 
 
 
 FEMALE 
 
from to APC 95%CI trend 
ESP 1976 1994 2013 5.9 4.6 7.2 ↑ 
       
ESP 2013 1994 2013 5.8 4.5 7.2 ↑ 
 
The incidence rate of in situ cervical cancer increased significantly by c.6% annually during 1994-2013, probably mainly due to 
screening, especially in the most recent years (Figure 3-15). As in situ cervical cancer is typically diagnosed in younger women 
(Figure 1-3), the actual rates themselves and the trend were very similar regardless of choice of ESP (1976 or 2013). 
 
Figure 3-16. Trend in incidence: C54 Uterine cancer 
 
 
 FEMALE 
 
from to APC 95%CI trend 
ESP 1976 1994 2013 2.5 1.9 3.0 ↑ 
       
ESP 2013 1994 2013 2.7 2.1 3.2 ↑ 
 
Incidence of uterine cancer (cancer of corpus uteri) increased significantly by c.2.5% annually during 1994-2013 (Figure 3-16). 
The trend was similar regardless of the choice of ESP (1976 or 2013). 
 
Figure 3-17. Trend in incidence: C56 Ovarian cancer 
 
 
 FEMALE 
 
from to APC 95%CI trend 
ESP 1976 1994 2013 -0.8 -1.4 -0.2 ↓ 
       
ESP 2013 1994 2013 -0.5 -1.0 0.0 ↔ 
 
The incidence rate of ovarian cancer decreased by <1% annually during 1994-2013 (Figure 3-17).  The downward trend was 
significant when the 1976 ESP was applied, but non-significant using the 2013 ESP. 
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Figure 3-18. Trend in incidence: C61 Prostate cancer 
 
 
 MALE 
 
from to APC 95%CI trend 
ESP 1976 1994 2004 7.8 6.1 9.6 ↑ 
ESP 1976 2004 2013 1.1 -0.3 2.5 ↔ 
       
ESP 2013 1994 2004 6.3 4.5 8.2 ↑ 
ESP 2013 2004 2013 0.0 -1.5 1.4 ↔ 
 
For prostate cancer, the incidence rate increased significantly between 1994 and 2004, by 6-8% annually (depending on 
which population standard is used). The increase then levelled off or slowed down (non-significant increase by c.1% annually, 
based on the 1976 ESP, or a flat trend based on the 2013 ESP*) (Figure 3-18). Increases in incidence during the earlier period, 
in particular, probably reflect large-scale PSA testing of asymptomatic men. The number of PSA tests carried out in Ireland 
increased five-fold between 1995 and 2004 [7]. [*The age-standardised trend based on the 2013 ESP is more strongly 
influenced by trends in older populations, and age-specific incidence of prostate cancer  has shown significant recent declines 
for age-groups 75-84 and 85+but not for younger age-groups – full details not presented here.] 
 
Figure 3-19. Trend in incidence by sex: C64 Kidney cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 3.0 2.4 3.5 ↑ 1994 2013 3.0 2.4 3.7 ↑ 
             
ESP 2013 1994 2013 2.9 2.2 3.7 ↑ 1994 2008 4.0 2.9 5.1 ↑ 
ESP 2013       2008 2013 0.4 -3.7 4.5 ↔ 
 
The incidence rate of kidney cancer increased by about 3% annually for males during 1994-2013 regardless of what ESP was 
applied (Figure 3-19). For females, rates calculated using the 1976 standard population indicated an ongoing increase by c.3% 
annually throughout 1994-2013, but for rates calculated with the 2013 ESP the rate increased up to 2008 (4% annually) 
followed by a levelling off up to 2013. 
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Figure 3-20. Trend in incidence by sex: C67 Bladder cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2006 -2.2 -3.0 -1.4 ↓ 1994 2013 -2.2 -3.2 -1.3 ↓ 
ESP 1976 2006 2013 -4.5 -6.3 -2.7 ↓       
             
ESP 2013 1994 2005 -1.7 -2.6 -0.8 ↓ 1994 2013 -1.8 -2.7 -0.8 ↓ 
ESP 2013 2005 2013 -3.9 -5.3 -2.4 ↓       
 
The incidence rate of bladder cancers coded as invasive decreased by c.2% annually in females over the period 1994-2013 
regardless of which ESP was applied. The rate in males also fell by c.2% annually until 2005-2006, after which the rate of 
decrease accelerated to c.4% annually. The point of break for males changed slightly depending on which ESP was used in the 
rate calculation. For both sexes, the magnitude of the downward trend may be exaggerated by changes in diagnosis or 
coding (in particular, a higher proportion of bladder tumours may have been coded as non-invasive in more recent years). It 
is not clear to what extent the trends reflect true changes in the underlying risk of bladder cancer. 
 
Figure 3-21. Trend in incidence by sex: C71-72 Brain & CNS cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 -0.3 -0.9 0.2 ↔ 1994 2013 0.4 -0.4 1.1 ↔ 
             
ESP 2013 1994 2013 0.1 -0.5 0.8 ↔ 1994 2013 0.5 -0.3 1.4 ↔ 
 
There were no significant change for males or females in the incidence rate of invasive brain/CNS tumours during the period 
1994-2013, regardless of the choice of ESP (1976 or 2013) (Figure 3-21). 
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Figure 3-22. Trend in incidence by sex: D32-D33 Benign neoplasm of brain & CNS 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 0.5 -0.9 1.9 ↔ 1994 2013 1.2 0.1 2.3 ↑ 
             
ESP 2013 1994 2013 1.3 -0.1 2.7 ↔ 1994 2013 1.9 0.8 3.0 ↑ 
 
For benign brain & CNS tumours, there was a 1-2% annual increase in the incidence rate in females during 1994-2013, and no 
significant change in the male incidence rate over the same period (Figure 2-22). For both sexes, rates calculated using the 
2013 ESP appeared to show stronger evidence of an increasing trend than rates calculated using the 1976 ESP. 
 
Figure 3-23. Trend in incidence by sex: D42-D43 Tumours of uncertain behaviour of brain, meninges & CNS 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 5.8 3.5 8.2 ↑ 1994 2013 8.5 5.9 11.2 ↑ 
             
ESP 2013 1994 2013 6.7 4.6 8.9 ↑ 1994 2013 9.4 6.6 12.3 ↑ 
 
Neoplasms of uncertain morphology for the brain, meninges and CNS are very rare, but there was a significant annual 
increase of 6-7% in males and 8-9% in females over the period 1994-2013 (Figure 3-23). This could be an artefact of coding or 
diagnosis changes: for example, a proportion of brain/CNS tumours that would previously have been coded as malignant or 
as benign might  now be appearing in the ‘uncertain’ category. The trend lines and actual rates appeared very similar 
regardless of which ESP was applied.  
 
Figure 3-24. Trend in incidence by sex: C73 Thyroid cancer 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 1999 -6.6 -20.0 8.9 ↔ 1994 2002 3.1 -3.3 9.9 ↔ 
ESP 1976 1999 2013 8.7 6.2 11.3 ↑ 2002 2013 10.9 8.2 13.7 ↑ 
             
ESP 2013 1994 1999 -9.4 -23.7 7.6 ↔ 1994 2001 0.6 -6.3 8.1 ↔ 
ESP 2013 1999 2013 8.6 5.8 11.5 ↑ 2001 2013 10.4 8.1 12.7 ↑ 
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Thyroid cancers are infrequent and between 2011 and 2013 they comprised just 2.2% of all female cancers and just 0.6% of 
male cancers (excluding NMSC). The female incidence rate increased significantly, by c.11% annually during 2002-2013 
(based on rates calculated using the 1976 ESP), while the male rate increased by c.9% annually during 1999-2013 (Figure 3-
24). For both sexes, these recent increases followed an earlier period in which there was no clear trend. The recent trends 
are likely to reflect an increase in ‘incidental’ detection of thyroid cancers during investigations for other conditions. The 
actual rate and trend lines appear similar (from 2005 to 2013) regardless of which ESP was applied, because thyroid cancers 
tend to present in younger persons (Figure 1-3).  
 
Figure 3-25. Trend in incidence by sex: C81-C85 Lymphoma (total) 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 1.7 1.3 2.1 ↑ 1994 2013 1.8 1.3 2.4 ↑ 
             
ESP 2013 1994 2013 2.2 1.7 2.6 ↑ 1994 2013 2.1 1.5 2.7 ↑ 
 
Lymphomas are a heterogeneous group of cancers of the haematopoietic system, classified as two distinct groups based on 
histological appearance. They comprise just under half of all haematopoietic cancers (which also include leukaemias, multiple 
myeloma and similar malignancies). The incidence rate for lymphomas as a whole increased steadily by c.2% annually in both 
sexes during the period 1994-2013, with similar trends apparent for rates based on the 1976 and 2013 standard populations 
(Figure 3-25). 
 
Figure 3-26. Trend in incidence by sex: C81 Hodgkin lymphoma 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 1.9 1.1 2.7 ↑ 1994 2013 2.0 0.6 3.4 ↑ 
             
ESP 2013 1994 2013 2.2 1.4 3.0 ↑ 1994 2013 1.7 0.3 3.2 ↑ 
 
The incidence rate for Hodgkin lymphoma increased steadily by c.2% annually in males and females during 1994-2013, 
regardless of which ESP was applied in the rate calculations (Figure 3-26). 
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Figure 3-27. Trend in incidence by sex: C82-C85 All non-Hodgkin lymphoma 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 1.7 1.2 2.1 ↑ 1994 2013 1.8 1.2 2.4 ↑ 
             
ESP 2013 1994 2013 2.2 1.7 2.7 ↑ 1994 2013 2.1 1.5 2.7 ↑ 
 
Non-Hodgkin lymphoma cases are diagnosed at approximately five times the frequency of Hodgkin lymphoma. Similarly to 
Hodgkin lymphomas, incidence rates for non-Hodgkin lymphoma increased significantly and steadily by c.2% annually in both 
males and females during the period 1994-2013, regardless of which ESP was applied in the rate calculations (Figure 3-27). 
 
Figure 3-28. Trend in incidence by sex: C90 Multiple myeloma and malignant plasma cell neoplasms 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2013 0.2 -0.4 0.9 ↔ 1994 1999 -4.0 -11.8 4.5 ↔ 
ESP 1976 
      
1999 2007 3.6 -1.4 8.8 ↔ 
ESP 1976 2007 2013 -6.0 -11.5 -0.2 ↓ 
             
ESP 2013 1994 2013 0.2 -0.5 1.0 ↔ 1994 2013 -0.3 -1.4 0.8 ↔ 
 
Multiple myeloma is a cancer of plasma cells (immunoglobulin-producing B-lymphocytes), where abnormal plasma cells 
accumulate in the bone marrow and interfere with haematopoiesis. The incidence rate showed no significant trend during 
the period 1994-2013 for males. In females, the modelled trend was static if calculated with the 2013 ESP, but the trend was 
more complex, including a significant downward trend by 6% annually from 2007 to 2013, if the 1976 ESP was applied to the 
rate calculation (Figure 3-28).  
 
Figure 3-29. Trend in incidence by sex: C91-C95 Leukaemia (total) 
 
 
 MALE FEMALE 
 
from to APC 95%CI trend from to APC 95%CI trend 
ESP 1976 1994 2004 3.5 1.4 5.6 ↑ 1994 2013 -0.1 -1.0 0.8 ↔ 
ESP 1976 2004 2013 -3.4 -5.4 -1.3 ↓       
             
ESP 2013 1994 2004 3.7 1.5 6.0 ↑ 1994 2008 1.2 -0.2 2.5 ↔ 
ESP 2013 2004 2013 -3.5 -5.6 -1.2 ↓ 2008 2013 -5.7 -11.2 0.0 ↔ 
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Leukaemia comprised about one quarter of all cancers of the haematopoietic system during 2011-2013. The incidence rate in 
males decreased significantly by c.3.5% annually during 2004-2013, following an earlier period of increase (again by c.3.5% 
annually). There was no clear trend in incidence among females over the same period, based on rates calculated using the 
1976 ESP, but rates calculated using the 2013 ESP showed  a downward trend from 2008 by almost 6% annually (not quite 
statistically significant) (Figure 3-29). 
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4. PREVALENCE 
 
Follow-up of all registered cancer patients (through matching of registrations to death certificates) is currently complete to 
the end of 2013. From the beginning of 1994 (when national cancer registration began in Ireland) to the end of 2013, a total 
of 137,467 females and 148,892 males were diagnosed with invasive cancer (excluding NMSC, and counting only the first 
invasive cancer per patient). Some 12% of these patients had more than one invasive cancer (other than NMSC) diagnosed 
during 1994-2013. In Table 4-1, which assesses prevalence of invasive cancer as a whole, patients were counted once only, 
choosing their first invasive cancer. Total prevalence for the 20 year period shows that 123,342 of these patients were still 
alive at the end of 2013, representing 47% of all females and 41% of males diagnosed with cancer since 1994 (or nearly 3% of 
the total Irish population in 2013) (Table 4-1). 
Note that figures given here are for period prevalence, i.e. based on cases diagnosed during a defined period. In reality, some 
patients diagnosed with cancer before 1994 will also have survived to the end of 2013. 
Table 4-1. Prevalence of invasive cancer (excluding non-melanoma skin cancer) in Ireland at the end of 2013  
 20-year prevalence 10-year prevalence 5-year prevalence 3-year prevalence 1-year prevalence 
Diagnosed 
from 
Jan 1994 Jan 2004 Jan 2009 Jan 2011 Jan 2013 
 alive 2013* %alive† alive 2013 % alive alive 2013 % alive alive 2013 % alive alive 2013 % alive 
all persons  123,342   44   91,164   58   56,841   68   37,453   74   13,943   84  
female  63,240   47   44,373   59   27,341   69   17,848   75   6,681   84  
male   60,102   41   46,791   56   29,500   67   19,605   73   7,262   83  
‡<65   55,193   57   43,516   70   28,861   79   19,321   84   7,269   92  
‡65+   68,149   37   47,648   50   27,980   59   18,132   65   6,674   76  
* alive 2013: number of persons diagnosed with an invasive cancer who were alive at the end of 2013 
‡ refers to age of patient at end of 2013 
†Figures for ‘% alive’ should not be interpreted as survival estimates because length of follow-up of individual patients is not accounted for. 
 
The majority of those still alive are patients diagnosed in the most recent ten years. Shorter-term prevalence can provide a 
good indicator of cancer burden - for example, one-year prevalence provides an estimate of the number of patients currently 
undergoing treatment or just recently completing their treatment (c.14,000), while three-year prevalence gives an includes 
the latter group together with patients who may have completed treatment but are still under more intensive clinical 
surveillance or follow-up (c.37,500).  
Prevalence figures are also presented in Tables 4-2 and 4-3 for the more common individual cancers. Note that some patients 
may be counted under more than one cancer type, but for these site-specific figures only the first cancer of each site or type 
is counted. Site-specific counts are presented as such because, e.g. a hypothetical patient with cancer of the breast (1
st
) 
followed by colon cancer some years later (2
nd
) generally undergoes two sets of treatment and follow-up protocols. 
Therefore, the healthcare resources involved, and the psychosocial or other impacts on the cancer survivor, are likely to be 
more substantial than would otherwise be the case. 
A total of 1,389 patients diagnosed with lung cancer during 2013 were still alive at the end of that year (one-year prevalence) 
(Table 4-2). This suggests that 59% of all patients diagnosed with lung cancer were likely to be still undergoing or just 
completing first-course treatment at that point. Three-year prevalence for lung cancer indicated that 2,592 patients were 
alive and likely to be still undergoing treatment or active clinical surveillance at the end of 2013. Lung cancer has very high 
mortality and, of the >37,000 cases diagnosed during 1994-2013, only 12% were alive at the close of 2013 (Table 4-2).   
Totals of 16,754 colorectal, 29,828 breast and 28,432 prostate cancer patients diagnosed since 1994 were still alive at the 
end of 2013, representing 40%, 67% and 63%, respectively, of those diagnosed since 1994 (Tables 4-2). These cancers all 
have a better prognosis than lung cancer, and focusing on those patients who are likely to be still under active treatment or 
clinical follow-up (three-year prevalence) gives totals for colorectal cancer of 5,550 (74% of all those diagnosed during 2011-
2013), for breast cancer 8,097 (93% of 2011-2013 cases) and 10,200 for prostate cancer (94% of 2011-2013 cases). 
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Table 4-2. Prevalence and ranks of common cancers 1994-2013 
 20-year prevalence 10-year prevalence 5-year prevalence 3-year prevalence 1-year prevalence 
Diagnosis period Jan 1994 to Dec 2013 Jan 2004 to Dec 2013 Jan 2009 to Dec 2013 Jan 2011 to Dec 2013 Jan 2013 to Dec 2013 
  N  alive 
end 2013  
 alive 
% 
rank   N  alive 
end 2013  
 alive 
% 
rank   N  alive 
end 2013  
 alive 
% 
rank   N  alive 
end 2013  
 alive 
% 
rank   N  alive 
end 2013  
 alive 
% 
ran
k  
C50 breast    44,772     29,828                  67          1     26,374     21,230                  81          2     14,303     12,720                89       2       8,752     8,097                93       2     2,983     2,882                97       2  
C61 prostate    45,418     28,432                  63          2     29,920     23,953                  80          1     16,624     14,868                89       1     10,200     9,540                94       1     3,213     3,140                98       1  
C18-20 colorectal    42,043     16,754                  40          3     23,509     12,593                  54          3     12,418       8,162                66       3       7,512     5,550                74       3     2,485     2,134                86       3  
C43 melanoma of skin    11,952       8,510                  71          4       7,639       6,097                  80          4       4,395       3,832                87       4       2,740     2,501                91       5        984        954                97       5  
C82-85 non-Hodgkin lymphoma    11,013       5,569                  51          5       6,561       4,132                  63          5       3,630       2,594                72       6       2,272     1,734                76       6        787        670                85       6  
C33-34 lung     37,097       4,512                  12          6     20,879       3,932                  19          6     11,285       3,190                28       5       6,955     2,592                37       4     2,338     1,389                59       4  
C54 corpus uteri      6,024       3,873                  64          7       3,679       2,735                  74          9       2,111       1,740                82       8       1,306     1,130                87       8        437        409                94       8  
C91-95 leukaemia       9,067       3,811                  42          8       5,024       2,770                  55          8       2,511       1,613                64       9       1,436        984                69       9        391        299                77     
12  
C67 bladder      9,211       3,654                  40          9       4,527       2,299                  51        10       2,209       1,321                60     10       1,321        879                67     10        420        332                79     
11  
C64 kidney      7,746       3,575                  46        10       4,858       2,792                  58          7       2,749       1,869                68       7       1,709     1,274                75       7        571        476                83       7  
C53 cervix      4,666       2,977                  64        11       2,816       2,044                  73        11       1,566       1,259                80     11          886        765                86     12        272        257                95     
15  
C62 testis      2,755       2,575                  94        12       1,673       1,616                  97        14          856          829                97     16          501        487                97     18        154        153                99     
20  
C01-14 mouth & pharynx      5,797       2,274                  39        13       3,399       1,793                  53        12       1,952       1,232                63     12       1,208        869                72     11        423        359                85       9  
C73 thyroid       2,581       2,031                  79        14       1,875       1,621                  87        13       1,212       1,093                90     13          824        758                92     13        304        280                92     
14  
C56  ovary      6,561       2,027                  31        15       3,480       1,418                  41        15       1,791          942                53     15       1,083        678                63     15        346        250                72     
16  
C16  stomach      9,853       1,717                  17        16       5,100       1,374                  27        16       2,688       1,009                38     14       1,597        742                47     14        506        342                68     
10  
C81 Hodgkin lymphoma      2,076       1,605                  77        17       1,216       1,012                  83        18          688          600                87     20          405        355                88     21        133        118                89     
23  
C71-72 brain & CNS      5,993       1,297                  22        18       3,295          909                  28        19       1,711          644                38     19       1,065        477                45     19        347        232                67     
17  
C90 multiple myeloma      4,381       1,253                  29        19       2,416       1,097                  45        17       1,266          776                61     17          748        540                72     16        256        220                86     
18  
C32 larynx      2,692       1,155                  43        20       1,518          873                  58        20          804          564                70     21          499        389                78     20        172        153                89     
20  
C15 oesophagus      6,785          999                  15        21       3,721          846                  23        21       1,913          655                34     18       1,167        510                44     17        404        292                72     
13  
C25 pancreas      8,230          589                    7        22       4,635          509                  11        22       2,438          422                17     22       1,489        353                24     22        500        215                43     
19  
C22 liver       2,737          430                  16        23       1,912          387                  20        23       1,124          321                29     23          728        263                36     23        257        130                51     
22  
N = number of cases diagnosed during diagnosis period, ranked by the number alive at end of 2013,  e.g. the highest 20-year prevalence was for breast cancer (C50), the highest 10- year prevalence was for prostate cancer (C61) 
For other less common cancers see Appendix IV: Prevalence 
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The majority (just over half) of all cancer patients in the 20-year prevalent population in at the end of 2013 were those who 
had first been diagnosed with breast, prostate and colorectal cancers. Other cancers with generally good prognoses, such as 
melanoma, also contributed a large proportion of the total (Table 4-2). Cancers with generally poor survival, such as 
pancreatic and oesophageal cancer, represented fairly low numbers in the prevalent population (Table 4-2). For example, out 
of almost 8,230 patients with pancreatic cancer diagnosed between 1994 and 2013, only 7% (589) were still alive at the close 
of 2013.  
 
In contrast, there were greater numbers of patients still alive who had been diagnosed with cancers with good prognoses, 
such as thyroid cancer where 20-year prevalence was 79% of all patients diagnosed with this cancer during 1994-2013 (Table 
4-2).  
 
Over 70% of known prostate, colorectal and bladder cancer survivors were over 65 at the end of 2013, reflecting their 
generally older age at diagnosis. In contrast, fewer than 15% of patients diagnosed with cancers of the cervix and Hodgkin 
lymphoma were over 65, indicative of their much younger age at diagnosis (Appendix IV). 
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5. SURVIVAL  
 
Net survival estimates to five years, including an assessment of recent survival changes, are presented here for three cancer 
types (colorectal cancer, female breast cancer, and cervical cancer), including a breakdown by HSE area of residence. Net 
survival is calculated by comparing the observed survival of patients with the expected survival of persons of the same age 
and sex in the general population. It represents the cumulative probability of a patient surviving a given time in the 
hypothetical situation in which the disease of interest is the only possible cause of death, i.e. survival having controlled for 
other possible cause of death.  
 
A more comprehensive summary of survival of Irish cancer patients was given in the previous NCR report covering longer-
term changes in survival, a longer list of cancer types and international comparisons [3]. See also the NCR website for further 
details of stage by site, sex, age, stage and area of residence [8]. 
 
Figure 5-1. Percentage 5-year net survival and 95% confidence intervals: colorectal cancer: 2003-2007 vs. 2008-2012 
NATIONAL HSE AREA 
  
 
 
Age-standardised, five-year net survival for colorectal cancer patients as a whole improved from 57% to 61% between 
diagnosis periods 2003-2007 and 2008-2012 (Figure 5-1).  Broadly similar improvements were also evident for male and 
female cases, and at regional scale. Regional variation in survival was not statistically significant, but survival appeared to be 
highest for patients living in the Dublin/Mid-Leinster and Dublin/North-East regions. 
  
56.6% 
60.7% 
56.9% 
61.8% 
56.5% 
59.8% 
0% 10% 20% 30% 40% 50% 60% 70%
2003-2007 
2008-2012 
2003-2007 
2008-2012 
2003-2007 
2008-2012 
IR
EL
A
N
D
 
IR
EL
A
N
D
 
IR
EL
A
N
D
 
A
LL
 
FE
M
A
LE
 
M
A
LE
 
5-year net survival % 
58.3% 
61.1% 
57.8% 
63.7% 
55.4% 
59.3% 
55.1% 
58.9% 
0% 10% 20% 30% 40% 50% 60% 70%
2003-2007 
2008-2012 
2003-2007 
2008-2012 
2003-2007 
2008-2012 
2003-2007 
2008-2012 
H
SE
 D
U
B
LI
N
/M
ID
-
LE
IN
ST
ER
 
H
SE
 
D
U
B
LI
N
/N
O
R
TH
-
EA
ST
 
H
SE
 S
O
U
TH
 
H
SE
 W
ES
T 
A
LL
 
5-year net survival % 
Page | 26  
 
Figure 5-2. Percentage 5-year net survival and 95% confidence intervals: breast cancer: 2003-2007 vs. 2008-2012 
  
 
 
Only minor improvements in breast cancer survival were seen between 2003-2007 and 2008-2012, from 80% to 82% net 
survival at five years, with similar patterns at regional scale (Figure 5-2). This follows more substantial improvements in 
survival between the mid/late 1990s and early 2000s noted in the previous annual report of the NCR [3]. Regional variation 
was also quite small, although survival appeared to be higher among patients living in the Dublin/Mid-Leinster and 
Dublin/North-East regions. 
 
Figure 5-3. Percentage 5-year net survival and 95% confidence intervals: cervical cancer: 2003-2007 vs. 2008-2012 
  
  
 
A substantial improvement in survival was noted for cervical cancer between 2003-2007 and 2008-2012, from 56% to 62% 
net survival at five years (Figure 5-3). Little or no improvement in cervical cancer had been seen in earlier years [8]. Three of 
the four HSE areas also showed evidence of improvements. However, confidence intervals on regional estimates are wide for 
this cancer, reflecting the small numbers of cases involved, thus it would be unsafe to draw any inferences about (apparent) 
regional variation in survival or in survival trends.  
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6. METHODS 
  
The National Cancer Registry was established by the Minister for Health in 1991. It has been collecting comprehensive cancer 
information for the Republic of Ireland since 1994. The information collected is used in research into the causes of cancer, in 
education and information programmes, and in the planning of cancer services to deliver the best cancer care to the whole 
population. Completeness of case ascertainment at five years after diagnosis is estimated to be at least 98% [9]. 
Incidence data are collected and coded by the NCR according to the ICDO3 classification (including translation from ICDO2 
codes for older data) [1]. For convenience, cancer types are specified or grouped in this report under ICD10-type codes, but 
these do not correspond to ‘strict’ ICD10 codes as some neoplasms classed as non-invasive / non-malignant under ICD10 (e.g. 
myelodysplastic syndrome, ICD10 D46) are now considered fully malignant under ICDO3. For such cases, the nearest 
equivalent malignant ICD10 code or subheading is used (thus polycythaemia vera, myelodysplastic syndromes and chronic 
myeloproliferative diseases have been included under C96, rather than D45-D47).  
Age-, sex- and cause-specific anonymised data for  deaths attributable to cancer and other neoplasms were downloaded 
from the Central Statistics Office website for years 2011 and 2012 [10]. At the time of compilation of this report, deaths for 
2013 (by year of death) were not available, and no update of the mortality trends presented in the last NCR report (for the 
years 1994-2012, [3]) has been attempted. 
 
The age-standardised (ASR) rate is the annual rate of newly 
diagnosed cases (or deaths) in a given population (and 
year), expressed per 100,000 persons (usually males and 
females separately), weighted by the age-structure of a 
defined ‘standard’ population, to allow meaningful 
comparisons between different countries over time. By 
convention for European cancer registries, age-
standardised rates for incidence and mortality were 
weighted by the European standard population (ESP) as 
defined in 1976 [2]. However, for the first time this report 
also presents rates weighted by the 2013 ESP proposed by 
EUROSTAT to more accurately reflect the demographic age 
shift in the European population since 1976 [4]. The 2013 
ESP is a better reflection of the current population 
structure than the ESP of 1976. The 2013 ESP gives older 
ages a greater weight than the 1976 ESP and also, while the 
1976 ESP has only one upper age band of 85+ years, the 
2013 ESP contains age bands of 85-89, 90-94 and 95+. Like 
most cancer registries, by convention the NCR pools case-
counts and population weights for age categories ‘<1 year’ 
and ’01-04 years’ (Table 6-1). 
 
 
Annual percentage changes (APC) of incidence over time (1994-2013) were estimated with the Joinpoint regression program, 
using annual age-standardised rates and their standard errors as inputs [5][6]. The same break point constraints for trend 
were applied to rates calculated using the 1976 ESP and 2013 ESP; a trend break point was allowed only after five 
consecutive years, and five years from either end of the year range. 
Table 6-1. Comparison of the 1976 ESP and the 2013 ESP  
population structures 
1976 ESP   2013 ESP 
age band weight per  
100,000  
  age band weight per  
100,000  
<1 1600   <1 1000 
01-04 6400   01-04 4000 
05-09 7000   05-09 5500 
10-14 7000   10-14 5500 
15-19 7000   15-19 5500 
20-24 7000   20-24 6000 
25-29 7000   25-29 6000 
30-34 7000   30-34 6500 
35-39 7000   35-39 7000 
40-44 7000   40-44 7000 
45-49 7000   45-49 7000 
50-54 7000   50-54 7000 
55-59 6000   55-59 6500 
60-64 5000   60-64 6000 
65-69 4000   65-69 5500 
70-74 3000   70-74 5000 
75-79 2000   75-79 4000 
80-84 1000   80-84 2500 
85+ 1000   85-89 1500 
      90-94 800 
      95+ 200 
Total 100,000   Total 100,000 
Source: EUROSTAT [4] 
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Survival figures presented in this report use net survival, an 'improved' version of relative survival taking better account of 
competing mortality risks and allowing greater comparability between different populations or age-groups. Net survival 
represents the cumulative probability of a patient surviving a given time in the hypothetical situation in which the disease of 
interest is the only possible cause of death, i.e. survival having controlled for other possible cause of death. (This involves 
comparison of observed survival with the expected survival of persons of the same age and gender in the general population, 
as for relative survival.) Net survival was calculated using the ‘strs’ command in STATA with an adjustment to obtain the 
Pohar-Perme estimate [11][12]. All survival estimates were age-standardised to the International Cancer Survival Standards 
(ICSS) [13].  
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APPENDIX I: SUMMARY TABLE - CANCER INCIDENCE: ANNUAL AVERAGE 2011-2013 
 
ICD10* cancer site (INCIDENCE) MALES FEMALES ALL 
N#: Average annual number of cases 2011-2013 rounded to nearest integer 
ASR‡: Age standardised rate/100,000- weighted by ESP of 1976  and 2013 
Risk†: Cumulative risk (%) to age 75 years 
N# % all  
invasive 
% all  
invasive 
ex. NMSC 
ASR‡ 
ESP 
1976 
ASR‡ 
ESP 
2013 
Risk† 
75Y 
N# % all  
invasive 
% all  
invasive 
ex. NMSC 
ASR‡ 
ESP 
1976 
ASR‡ 
ESP 
2013 
Risk† 
75Y 
% 
N# % all  
invasive 
% all  
invasive 
ex. NMSC 
C00-C96: All invasive cancers*                16,240  100.0%  723.8 1125.7 44.40                13,726  100.0%  546.0 791.6 35.05                29,966  100.0%  
C00-C43, C45-C96 all invasive cancers, excluding NMSC                10,948  67.4% 100.0% 489.5 741.9 33.68                   9,506  69.3% 100.0% 384.1 540.3 26.45                20,454  68.3% 100.0% 
C00-D48 all registered tumours                17,848    795.1 1236.5 47.44                19,215    763.7 1040.0 44.86                37,062    
D00-D48: All non-invasive tumours**                   1,608    71.3 110.8 5.46                   5,488    217.7 248.3 15.11                   7,096    
C01 Malignant neoplasm of base of tongue                          26  0.2% 0.2% 1.2 1.5 0.11                             9  0.1% 0.1% 0.4 0.5 0.04                          35  0.1% 0.2% 
C00 Malignant neoplasm of lip                          17  0.1% 0.2% 0.8 1.4 0.06                             6  <0.1% 0.1% 0.2 0.3 0.01                          23  0.1% 0.1% 
C02 Malignant neoplasm of other and unspecified parts of tongue                          48  0.3% 0.4% 2.1 2.9 0.19                          27  0.2% 0.3% 1.1 1.5 0.09                          75  0.3% 0.4% 
C03 Malignant neoplasm of gum                          10  0.1% 0.1% 0.5 0.6 0.05                             8  0.1% 0.1% 0.3 0.5 0.03                          18  0.1% 0.1% 
C04 Malignant neoplasm of floor of mouth                          27  0.2% 0.2% 1.3 1.6 0.12                             7  0.1% 0.1% 0.3 0.4 0.03                          34  0.1% 0.2% 
C05 Malignant neoplasm of palate                          12  0.1% 0.1% 0.5 0.7 0.04                             6  <0.1% 0.1% 0.2 0.3 0.01                          17  0.1% 0.1% 
C06 Malignant neoplasm of other and unspecified parts of mouth                          15  0.1% 0.1% 0.7 1.0 0.05                          16  0.1% 0.2% 0.6 0.9 0.04                          31  0.1% 0.2% 
C07 Malignant neoplasm of parotid gland                          19  0.1% 0.2% 0.8 1.3 0.06                          12  0.1% 0.1% 0.5 0.6 0.04                          31  0.1% 0.2% 
C08 Malignant neoplasm of other and unspecified major salivary glands                             4  <0.1% <0.1% 0.2 0.3 0.01                             3  <0.1% <0.1% 0.1 0.2 0.01                             7  <0.1% <0.1% 
C09 Malignant neoplasm of tonsil                          42  0.3% 0.4% 1.9 2.3 0.17                          12  0.1% 0.1% 0.5 0.6 0.04                          54  0.2% 0.3% 
C10 Malignant neoplasm of oropharynx                          18  0.1% 0.2% 0.8 1.2 0.07                             5  <0.1% 0.1% 0.2 0.3 0.02                          24  0.1% 0.1% 
C11 Malignant neoplasm of nasopharynx                          12  0.1% 0.1% 0.5 0.6 0.05                             5  <0.1% 0.1% 0.2 0.3 0.02                          17  0.1% 0.1% 
C12 Malignant neoplasm of pyriform sinus                          23  0.1% 0.2% 1.0 1.4 0.10                             3  <0.1% <0.1% 0.1 0.2 0.01                          26  0.1% 0.1% 
C13 Malignant neoplasm of hypopharynx                          14  0.1% 0.1% 0.6 0.9 0.05                             5  <0.1% 0.1% 0.2 0.3 0.01                          18  0.1% 0.1% 
C14 Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx                          12  0.1% 0.1% 0.5 0.7 0.05                             5  <0.1% 0.1% 0.2 0.3 0.01                          17  0.1% 0.1% 
C01-14 Malignant neoplasm of mouth & pharynx                       280  1.7% 2.6% 12.7 16.9 1.12                       122  0.9% 1.3% 5.1 6.8 0.41                       403  1.3% 2.0% 
C15 Malignant neoplasm of oesophagus                       251  1.5% 2.3% 11.3 17.6 0.95                       138  1.0% 1.5% 5.0 8.5 0.36                       389  1.3% 1.9% 
C16 Malignant neoplasm of stomach                       341  2.1% 3.1% 15.1 24.7 1.18                       192  1.4% 2.0% 7.1 11.6 0.50                       532  1.8% 2.6% 
C17 Malignant neoplasm of small intestine                          49  0.3% 0.4% 2.2 3.2 0.18                          33  0.2% 0.3% 1.3 1.9 0.10                          82  0.3% 0.4% 
C18 Malignant neoplasm of colon                       882  5.4% 8.1% 39.1 64.7 2.87                       731  5.3% 7.7% 27.6 44.2 2.02                   1,614  5.4% 7.9% 
C19 Malignant neoplasm of rectosigmoid junction                       106  0.7% 1.0% 4.7 7.5 0.39                          57  0.4% 0.6% 2.2 3.4 0.19                       163  0.5% 0.8% 
C20 Malignant neoplasm of rectum                       452  2.8% 4.1% 20.2 30.7 1.71                       231  1.7% 2.4% 9.3 13.6 0.75                       683  2.3% 3.3% 
C21 Malignant neoplasm of anus and anal canal                          19  0.1% 0.2% 0.8 1.3 0.07                          25  0.2% 0.3% 1.0 1.4 0.08                          44  0.1% 0.2% 
C19-20 Malignant neoplasm of rectosigmoid junction and rectum                       558  3.4% 5.1% 24.9 38.2 2.09                       288  2.1% 3.0% 11.5 17.0 0.93                       846  2.8% 4.1% 
C18-20 Malignant neoplasm of colon and rectum                   1,441  8.9% 13.2% 64.0 102.9 4.90                   1,019  7.4% 10.7% 39.0 61.2 2.93                   2,460  8.2% 12.0% 
C18-21 Malignant neoplasm of colon, rectum and anus                   1,460  9.0% 13.3% 64.8 104.2 4.96                   1,044  7.6% 11.0% 40.1 62.6 3.01                   2,504  8.4% 12.2% 
C22 Malignant neoplasm of liver and intrahepatic bile ducts                       167  1.0% 1.5% 7.4 11.6 0.58                          75  0.5% 0.8% 2.8 4.5 0.21                       243  0.8% 1.2% 
C23 Malignant neoplasm of gallbladder                          16  0.1% 0.1% 0.7 1.3 0.04                          41  0.3% 0.4% 1.5 2.6 0.10                          57  0.2% 0.3% 
C24 Malignant neoplasm of other and unspecified parts of biliary tract                          55  0.3% 0.5% 2.4 4.1 0.18                          53  0.4% 0.6% 1.9 3.3 0.12                       109  0.4% 0.5% 
C25 Malignant neoplasm of pancreas                       259  1.6% 2.4% 11.5 18.9 0.89                       238  1.7% 2.5% 8.7 14.8 0.62                       496  1.7% 2.4% 
C26 Malignant neoplasm of other and ill-defined digestive organs                          14  0.1% 0.1% 0.6 1.1 0.04                          19  0.1% 0.2% 0.6 1.1 0.03                          33  0.1% 0.2% 
C30 Malignant neoplasm of nasal cavity and middle ear                             6  <0.1% 0.1% 0.3 0.4 0.02                             6  <0.1% 0.1% 0.3 0.3 0.02                          12  <0.1% 0.1% 
C31 Malignant neoplasm of accessory sinuses                             6  <0.1% 0.1% 0.3 0.4 0.02                             5  <0.1% 0.1% 0.2 0.3 0.02                          10  <0.1% <0.1% 
C32 Malignant neoplasm of larynx                       140  0.9% 1.3% 6.3 8.9 0.54                          27  0.2% 0.3% 1.1 1.5 0.11                       166  0.6% 0.8% 
C33 Malignant neoplasm of trachea                             1  <0.1% <0.1% 0.1 0.1 <0.01                             1  <0.1% <0.1% 0.1 0.1 <0.01                             2  <0.1% <0.1% 
C34 Malignant neoplasm of bronchus and lung                   1,290  7.9% 11.8% 57.3 94.0 4.45                   1,026  7.5% 10.8% 40.2 62.9 3.29                   2,316  7.7% 11.3% 
C33-34 Malignant neoplasm of lung and trachea                   1,292  8.0% 11.8% 57.3 94.1 4.45                   1,027  7.5% 10.8% 40.3 63.0 3.29                   2,318  7.7% 11.3% 
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ICD10* cancer site (INCIDENCE) MALES FEMALES ALL 
N#: Average annual number of cases 2011-2013 rounded to nearest integer 
ASR‡: Age standardised rate/100,000- weighted by ESP of 1976  and 2013 
Risk†: Cumulative risk (%) to age 75 years 
N# % all  
invasive 
% all  
invasive 
ex. NMSC 
ASR‡ 
ESP 
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ASR‡ 
ESP 
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75Y 
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% all  
invasive 
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ASR‡ 
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% 
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invasive 
% all  
invasive 
ex. NMSC 
C37 Malignant neoplasm of thymus                             5  <0.1% <0.1% 0.2 0.3 0.01                             5  <0.1% 0.1% 0.2 0.3 0.02                          10  <0.1% <0.1% 
C38 Malignant neoplasm of heart, mediastinum and pleura                          10  0.1% 0.1% 0.4 0.7 0.03                             3  <0.1% <0.1% 0.1 0.2 0.01                          13  <0.1% 0.1% 
C40 Malignant neoplasm of bone and articular cartilage of limbs                          14  0.1% 0.1% 0.6 0.7 0.05                             9  0.1% 0.1% 0.4 0.4 0.03                          22  0.1% 0.1% 
C41 Malignant neoplasm of bone and articular cartilage of other and unspecified sites                          11  0.1% 0.1% 0.5 0.6 0.03                             7  0.1% 0.1% 0.3 0.3 0.03                          18  0.1% 0.1% 
C43 Malignant melanoma of skin                       422  2.6% 3.9% 18.7 27.1 1.46                       491  3.6% 5.2% 19.8 26.4 1.56                       913  3.0% 4.5% 
C44 Other malignant neoplasms of skin                   5,292  32.6%  234.4 383.9 16.18                   4,220  30.7%  161.9 251.4 11.69                   9,512  31.7%  
C45 Mesothelioma                          37  0.2% 0.3% 1.6 2.7 0.15                             6  <0.1% 0.1% 0.2 0.3 0.02                          43  0.1% 0.2% 
C46 Kaposi sarcoma                          10  0.1% 0.1% 0.4 0.5 0.03                             1  <0.1% <0.1% <0.1 <0.1 <0.01                          11  <0.1% 0.1% 
C47 Malignant neoplasm of peripheral nerves and autonomic nervous system                             3  <0.1% <0.1% 0.1 0.1 0.01                             2  <0.1% <0.1% 0.1 0.1 <0.01                             5  <0.1% <0.1% 
C48 Malignant neoplasm of retroperitoneum and peritoneum                             7  <0.1% 0.1% 0.3 0.5 0.02                          20  0.1% 0.2% 0.8 1.2 0.07                          27  0.1% 0.1% 
C49 Malignant neoplasm of other connective and soft tissue                          64  0.4% 0.6% 2.8 4.1 0.20                          43  0.3% 0.5% 1.8 2.4 0.13                       107  0.4% 0.5% 
C50 Malignant neoplasm of breast                          34  0.2% 0.3% 1.5 2.4 0.12                   2,883  21.0% 30.3% 122.6 157.5 9.61                   2,917  9.7% 14.3% 
C51 Malignant neoplasm of vulva                                49  0.4% 0.5% 1.9 2.8 0.15                          49  0.2% 0.2% 
C52 Malignant neoplasm of vagina                                14  0.1% 0.1% 0.5 0.8 0.04                          14  <0.1% 0.1% 
C53 Malignant neoplasm of cervix uteri                             295  2.1% 3.1% 12.4 13.6 0.96                       295  1.0% 1.4% 
C54 Malignant neoplasm of corpus uteri                             435  3.2% 4.6% 18.6 25.3 1.64                       435  1.5% 2.1% 
C55 Malignant neoplasm of uterus, part unspecified                                22  0.2% 0.2% 0.9 1.3 0.07                          22  0.1% 0.1% 
C56 Malignant neoplasm of ovary                             361  2.6% 3.8% 14.8 20.6 1.19                       361  1.2% 1.8% 
C57 Malignant neoplasm of other and unspecified female genital organs                                15  0.1% 0.2% 0.6 0.9 0.05                          15  0.1% 0.1% 
C58 Malignant neoplasm of placenta                                   3  <0.1% <0.1% 0.1 0.1 0.01                             3  <0.1% <0.1% 
C51-52,55,57,58 Malignancies of vulva, vagina, uterus (NOS), unspecified female genital & placenta                             102  0.7% 1.1% 4.1 5.9 0.31                       102  0.3% 0.5% 
C60 Malignant neoplasm of penis                          33  0.2% 0.3% 1.5 2.2 0.10                                33  0.1% 0.2% 
C61 Malignant neoplasm of prostate                   3,400  20.9% 31.1% 154.3 224.6 13.77                         3,400  11.3% 16.6% 
C62 Malignant neoplasm of testis                       167  1.0% 1.5% 7.0 6.7 0.50                             167  0.6% 0.8% 
C63 Malignant neoplasm of other and unspecified male genital organs                             4  <0.1% <0.1% 0.2 0.3 0.01                                   4  <0.1% <0.1% 
C64 Malignant neoplasm of kidney, except renal pelvis                       373  2.3% 3.4% 16.7 23.7 1.35                       197  1.4% 2.1% 8.0 11.4 0.68                       570  1.9% 2.8% 
C65 Malignant neoplasm of renal pelvis                          17  0.1% 0.2% 0.7 1.3 0.05                             8  0.1% 0.1% 0.3 0.5 0.03                          25  0.1% 0.1% 
C66 Malignant neoplasm of ureter                          13  0.1% 0.1% 0.6 0.9 0.05                             6  <0.1% 0.1% 0.2 0.4 0.02                          19  0.1% 0.1% 
C67 Malignant neoplasm of bladder                       306  1.9% 2.8% 13.5 23.7 0.95                       135  1.0% 1.4% 4.9 8.3 0.33                       440  1.5% 2.2% 
C68 Malignant neoplasm of other and unspecified urinary organs                             3  <0.1% <0.1% 0.1 0.2 0.01                             2  <0.1% <0.1% 0.1 0.1 <0.01                             5  <0.1% <0.1% 
C69 Malignant neoplasm of eye and adnexa                          33  0.2% 0.3% 1.5 1.9 0.13                          26  0.2% 0.3% 1.1 1.4 0.09                          60  0.2% 0.3% 
C70 Malignant neoplasm of meninges                             4  <0.1% <0.1% 0.2 0.3 0.01                             6  <0.1% 0.1% 0.2 0.3 0.02                          10  <0.1% <0.1% 
C71 Malignant neoplasm of brain                       192  1.2% 1.8% 8.5 11.3 0.71                       149  1.1% 1.6% 6.2 7.9 0.49                       341  1.1% 1.7% 
C72 Malignant neoplasm of spinal cord, cranial nerves and other parts of CNS                             7  <0.1% 0.1% 0.3 0.3 0.02                             7  0.1% 0.1% 0.3 0.3 0.02                          14  <0.1% 0.1% 
C71-72 Malignant neoplasm of brain and spinal cord                       199  1.2% 1.8% 8.8 11.6 0.73                       156  1.1% 1.6% 6.4 8.2 0.51                       355  1.2% 1.7% 
C73 Malignant neoplasm of thyroid gland                          69  0.4% 0.6% 3.0 3.7 0.25                       205  1.5% 2.2% 8.6 9.7 0.68                       275  0.9% 1.3% 
C74 Malignant neoplasm of adrenal gland                             9  0.1% 0.1% 0.4 0.4 0.03                             8  0.1% 0.1% 0.3 0.3 0.02                          17  0.1% 0.1% 
C75 Malignant neoplasm of other endocrine glands and related structures                             8  <0.1% 0.1% 0.3 0.4 0.03                             6  <0.1% 0.1% 0.2 0.3 0.01                          14  <0.1% 0.1% 
C76 Malignant neoplasm of other and ill-defined sites                             7  <0.1% 0.1% 0.3 0.4 0.03                          15  0.1% 0.2% 0.5 0.9 0.04                          22  0.1% 0.1% 
C77 Secondary and unspecified malignant neoplasm of lymph nodes                             2  <0.1% <0.1% 0.1 0.1 <0.01                             1  <0.1% <0.1% <0.1 <0.1 <0.01                             3  <0.1% <0.1% 
C80 Malignant neoplasm without specification of site                       215  1.3% 1.9% 9.6 16.3 0.65                       227  1.6% 2.4% 7.9 13.9 0.52                       442  1.5% 2.1% 
C81 Hodgkin lymphoma                          75  0.5% 0.7% 3.3 3.6 0.25                          60  0.4% 0.6% 2.6 2.8 0.20                       135  0.5% 0.7% 
C82 Follicular [nodular] non-Hodgkin lymphoma                          82  0.5% 0.7% 3.7 4.8 0.32                       101  0.7% 1.1% 4.3 5.7 0.38                       183  0.6% 0.9% 
C83 Diffuse non-Hodgkin lymphoma                       204  1.3% 1.9% 9.1 13.5 0.71                       148  1.1% 1.6% 5.9 8.7 0.48                       352  1.2% 1.7% 
C84 Peripheral and cutaneous T-cell lymphomas                          37  0.2% 0.3% 1.6 2.3 0.13                          25  0.2% 0.3% 1.0 1.4 0.09                          61  0.2% 0.3% 
C85 Other and unspecified types of non-Hodgkin lymphoma                          83  0.5% 0.8% 3.6 5.8 0.27                          78  0.6% 0.8% 3.0 4.7 0.23                       161  0.5% 0.8% 
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ICD10* cancer site (INCIDENCE) MALES FEMALES ALL 
N#: Average annual number of cases 2011-2013 rounded to nearest integer 
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Risk†: Cumulative risk (%) to age 75 years 
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C82-85 All non-Hodgkin lymphoma                       406  2.5% 3.7% 18.1 26.4 1.42                       352  2.6% 3.7% 14.2 20.5 1.18                       757  2.5% 3.7% 
C81-85 Lymphoma (total)                       480  3.0% 4.4% 21.4 30.0 1.67                       412  3.0% 4.3% 16.8 23.2 1.38                       892  3.0% 4.4% 
C88 Malignant immunoproliferative diseases                          12  0.1% 0.1% 0.5 0.9 0.04                             7  0.1% 0.1% 0.3 0.4 0.03                          19  0.1% 0.1% 
C90 Multiple myeloma and malignant plasma cell neoplasms                       153  0.9% 1.4% 6.8 10.8 0.51                          96  0.7% 1.0% 3.6 5.8 0.26                       249  0.8% 1.2% 
C91 Lymphoid leukaemia                       164  1.0% 1.5% 7.4 10.7 0.55                          98  0.7% 1.0% 4.1 5.3 0.32                       263  0.9% 1.3% 
C92 Myeloid leukaemia                       101  0.6% 0.9% 4.5 6.9 0.32                          75  0.5% 0.8% 3.0 4.1 0.24                       175  0.6% 0.9% 
C93 Monocytic leukaemia                             2  <0.1% <0.1% 0.1 0.1 <0.01                             2  <0.1% <0.1% 0.1 0.1 0.01                             4  <0.1% <0.1% 
C94 Other leukaemias of specified cell type                             6  <0.1% 0.1% 0.3 0.4 0.02                             2  <0.1% <0.1% 0.1 0.1 <0.01                             8  <0.1% <0.1% 
C95 Leukaemia of unspecified cell type                          17  0.1% 0.2% 0.8 1.6 0.03                          13  0.1% 0.1% 0.4 0.7 0.02                          29  0.1% 0.1% 
C91-C95 Leukaemia (total)                       289  1.8% 2.6% 12.9 19.7 0.93                       190  1.4% 2.0% 7.6 10.3 0.59                       479  1.6% 2.3% 
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue*                       183  1.1% 1.7% 8.1 13.4 0.58                       118  0.9% 1.2% 4.5 7.1 0.34                       301  1.0% 1.5% 
D01 Carcinoma in situ of other and unspecified digestive organs                          20    0.9 1.3 0.07                          19    0.8 1.0 0.07                          39    
D02 Carcinoma in situ of middle ear and respiratory system                             9    0.4 0.6 0.04                             9    0.4 0.5 0.03                          18    
D03 Melanoma in situ                       264    11.8 17.2 0.95                       294    12.0 16.5 1.00                       558    
D04 Carcinoma in situ of skin                       714    31.5 51.9 2.45                   1,048    39.1 65.5 2.99                   1,762    
D05 Carcinoma in situ of breast                             1    <0.1 <0.1 <0.01                       360    16.4 18.7 1.34                       361    
D06 Carcinoma in situ of cervix uteri                         3,213    126.4 117.5 8.69                   3,213    
D32 Benign neoplasm of meninges                          35    1.6 2.4 0.12                          99    4.0 5.5 0.33                       134    
D33 Benign neoplasm of brain and other parts of CNS                          19    0.9 1.0 0.07                          21    0.9 1.0 0.07                          40    
D32-D33 Benign neoplasm of meninges, brain & CNS                          55    2.4 3.4 0.20                       120    4.9 6.6 0.40                       175    
D42 Neoplasm of uncertain or unknown behaviour of meninges                             6    0.3 0.3 0.02                             8    0.3 0.4 0.03                          15    
D43 Neoplasm of uncertain or unknown behaviour of brain and CNS                          26    1.1 1.1 0.08                          27    1.1 1.2 0.08                          52    
D42-D43 Neoplasm of uncertain meninges, brain & CNS                          32    1.4 1.5 0.10                          35    1.5 1.6 0.10                          67    
C71-72, D32-33, D42-43 All malignant, benign, uncertain neoplasms of brain and CNS                       285    12.7 16.4 1.02                       311    12.9 16.4 1.01                       597    
*Incidence figures for C00-C96 and C96 presented in this report include polycythaemia vera, myelodysplastic syndromes and chronic myeloproliferative disease, considered malignant in ICDO3 but previously classed as uncertain behaviour (and 
previously coded under ICD10 codes D45-D47).  
** D00-D48 tumours in this report exclude polycythaemia vera, myelodysplastic syndromes and chronic myeloproliferative disease (see note above).   
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APPENDIX II: SUMMARY TABLE - CANCER DEATHS: ANNUAL AVERAGE 2011-2012 
 
 ICD10 cancer site (MORTALITY) MALES FEMALES ALL 
N#: Average annual number of deaths 2011-2012 rounded to nearest integer 
ASR‡: Age standardised rate/100,000 - weighted by ESP of 1976  
Risk†: Cumulative risk of death (%) due to listed cancer up to age 75 years 
N# % of all 
neoplasm 
deaths 
ASR‡ 
ESP 
1976 
Risk† 
75Y 
N# % of all 
neoplasm 
deaths 
ASR‡ 
ESP 
1976 
Risk† 
75Y 
% 
N# % of all 
neoplasm 
deaths 
C00-D48 all neoplasms/tumours 4,692  100.0% 211.1  12.90  4,135  100.0% 152.9  10.26  8,827  100.0% 
C00-C96: All invasive cancers 4,581  97.6% 206.1  12.70  4,038  97.7% 149.9  10.12  8,619  97.6% 
C00-C43, C45-C96 all invasive cancers, excluding NMSC 4,539  96.7% 204.1  12.60  4,012  97.0% 149.1  10.10  8,551  96.9% 
D00-D48: All non-invasive neoplasms/tumours 111  2.4% 5.0  0.22  97  2.3% 3.1  0.15  208  2.4% 
C01 Malignant neoplasm of base of tongue 5  0.1% 0.2  0.02  1  0.0% <0.1 <0.01  6  0.1% 
C00 Malignant neoplasm of lip 3  0.1% 0.1  0.00  0  0.0% 0.0 <0.01 3  0.0% 
C02 Malignant neoplasm of other and unspecified parts of tongue 21  0.4% 0.9  0.09  15  0.4% 0.6  0.05  36  0.4% 
C03 Malignant neoplasm of gum 2  0.0% 0.1  0.00  2  0.0% 0.1  <0.01 4  0.0% 
C04 Malignant neoplasm of floor of mouth 6  0.1% 0.3  0.03  1  0.0% <0.1 <0.01 7  0.1% 
C05 Malignant neoplasm of palate 3  0.1% 0.1  0.01  2  0.0% 0.1  <0.01 5  0.1% 
C06 Malignant neoplasm of other and unspecified parts of mouth 9  0.2% 0.4  0.03  6  0.1% 0.2  0.01  15  0.2% 
C07 Malignant neoplasm of parotid gland 6  0.1% 0.3  0.01  6  0.1% 0.2  0.01  12  0.1% 
C08 Malignant neoplasm of other and unspecified major salivary glands 2  0.0% 0.1  0.00  3  0.1% 0.1  0.01  5  0.1% 
C09 Malignant neoplasm of tonsil 10  0.2% 0.4  0.04  2  0.0% 0.1  <0.01 12  0.1% 
C10 Malignant neoplasm of oropharynx 14  0.3% 0.6  0.05  2  0.0% 0.1  <0.01 16  0.2% 
C11 Malignant neoplasm of nasopharynx 9  0.2% 0.4  0.04  4  0.1% 0.2  0.01  13  0.1% 
C12 Malignant neoplasm of pyriform sinus 7  0.1% 0.3  0.03  2  0.0% 0.1  0.01  9  0.1% 
C13 Malignant neoplasm of hypopharynx 5  0.1% 0.2  0.01  3  0.1% 0.1  <0.01 8  0.1% 
C14 Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx 19  0.4% 0.9  0.09  4  0.1% 0.2  0.01  23  0.3% 
C01-14 Malignant neoplasm of mouth & pharynx 114  2.4% 5.2  0.44  50  1.2% 1.9  0.14  164  1.9% 
C15 Malignant neoplasm of oesophagus 231  4.9% 10.5  0.81  137  3.3% 4.8  0.32  368  4.2% 
C16 Malignant neoplasm of stomach 201  4.3% 9.0  0.60  120  2.9% 4.1  0.25  321  3.6% 
C17 Malignant neoplasm of small intestine 12  0.3% 0.5  0.02  13  0.3% 0.5  0.01  25  0.3% 
C18 Malignant neoplasm of colon 296  6.3% 13.3  0.83  248  6.0% 8.3  0.51  544  6.2% 
C19 Malignant neoplasm of rectosigmoid junction 186  4.0% 8.4  0.61  98  2.4% 3.7  0.27  284  3.2% 
C20 Malignant neoplasm of rectum 110  2.3% 4.9  0.29  63  1.5% 2.2  0.14  173  2.0% 
C21 Malignant neoplasm of anus and anal canal 5  0.1% 0.2  0.01  7  0.2% 0.3  0.03  12  0.1% 
C19-20 Malignant neoplasm of rectosigmoid junction and rectum 295  6.3% 13.2  0.90  161  3.9% 6.0  0.41  456  5.2% 
C18-20 Malignant neoplasm of colon and rectum 591  12.6% 26.5  1.73  409  9.9% 14.3  0.91  1,000  11.3% 
C18-21 Malignant neoplasm of colon, rectum and anus 596  12.7% 26.8  1.74  416  10.1% 14.6  0.94  1,012  11.5% 
C22 Malignant neoplasm of liver and intrahepatic bile ducts 143  3.0% 6.5  0.49  106  2.6% 3.8  0.25  249  2.8% 
C23 Malignant neoplasm of gallbladder 9  0.2% 0.4  0.03  20  0.5% 0.7  0.04  29  0.3% 
C24 Malignant neoplasm of other and unspecified parts of biliary tract 9  0.2% 0.4  0.03  12  0.3% 0.4  0.03  21  0.2% 
C25 Malignant neoplasm of pancreas 251  5.3% 11.3  0.78  226  5.5% 8.2  0.55  477  5.4% 
C26 Malignant neoplasm of other and ill-defined digestive organs 72  1.5% 3.2  0.19  63  1.5% 2.1  0.13  135  1.5% 
C30 Malignant neoplasm of nasal cavity and middle ear 1  0.0% <0.1 0.00  2  0.0% 0.1  <0.01 3  0.0% 
C31 Malignant neoplasm of accessory sinuses 2  0.0% 0.1  0.01  3  0.1% 0.1  <0.01 5  0.1% 
C32 Malignant neoplasm of larynx 57  1.2% 2.6  0.19  10  0.2% 0.4  0.04  67  0.8% 
C33 Malignant neoplasm of trachea 1  0.0% <0.1 0.00  1  0.0% <0.1 <0.01 2  0.0% 
C34 Malignant neoplasm of bronchus and lung 1,081  23.0% 48.5  3.52  744  18.0% 28.4  2.14  1,825  20.7% 
C33-34 Malignant neoplasm of lung and trachea 1,081  23.0% 48.5  3.53  745  18.0% 28.4  2.14  1,826  20.7% 
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 ICD10 cancer site (MORTALITY) MALES FEMALES ALL 
N#: Average annual number of deaths 2011-2012 rounded to nearest integer 
ASR‡: Age standardised rate/100,000 - weighted by ESP of 1976  
Risk†: Cumulative risk of death (%) due to listed cancer up to age 75 years 
N# % of all 
neoplasm 
deaths 
ASR‡ 
ESP 
1976 
Risk† 
75Y 
N# % of all 
neoplasm 
deaths 
ASR‡ 
ESP 
1976 
Risk† 
75Y 
% 
N# % of all 
neoplasm 
deaths 
C37 Malignant neoplasm of thymus 1  0.0% <0.1 <0.01 2  0.0% 0.1  <0.01 3  0.0% 
C38 Malignant neoplasm of heart, mediastinum and pleura 1  0.0% <0.1 <0.01 1  0.0% <0.1 <0.01 2  0.0% 
C39 Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs 1  0.0% <0.1 <0.01 0 0.0%   1  0.0% 
C40 Malignant neoplasm of bone and articular cartilage of limbs 2  0.0% 0.1  <0.01 1  0.0% <0.1 <0.01 3  0.0% 
C41 Malignant neoplasm of bone and articular cartilage of other and unspecified sites 9  0.2% 0.4  0.03  6  0.1% 0.2  0.01  15  0.2% 
C43 Malignant melanoma of skin 84  1.8% 3.7  0.26  65  1.6% 2.4  0.16  149  1.7% 
C44 Other malignant neoplasms of skin 42  0.9% 1.9  0.11  27  0.7% 0.8  0.02  69  0.8% 
C45 Mesothelioma 31  0.7% 1.3  0.09  5  0.1% 0.2  0.01  36  0.4% 
C46 Kaposi sarcoma 0  0.0% 0.0 0.00 0 0.0%   0  0.0% 
C47 Malignant neoplasm of peripheral nerves and autonomic nervous system 0  0.0% 0.0 0.00 1  0.0% <0.1 <0.01 1  0.0% 
C48 Malignant neoplasm of retroperitoneum and peritoneum 3  0.1% 0.1  0.01  14  0.3% 0.5  0.05  17  0.2% 
C49 Malignant neoplasm of other connective and soft tissue 31  0.7% 1.4  0.09  20  0.5% 0.8  0.07  51  0.6% 
C50 Malignant neoplasm of breast 8  0.2% 0.4  0.03  690  16.7% 26.7  1.99  698  7.9% 
C51 Malignant neoplasm of vulva     17  0.4% 0.5  0.03  17  0.2% 
C52 Malignant neoplasm of vagina     5  0.1% 0.2  0.01  5  0.1% 
C53 Malignant neoplasm of cervix uteri     96  2.3% 4.1  0.32  96  1.1% 
C54 Malignant neoplasm of corpus uteri     78  1.9% 2.9  0.22  78  0.9% 
C55 Malignant neoplasm of uterus, part unspecified     27  0.7% 1.0  0.07  27  0.3% 
C56 Malignant neoplasm of ovary     277  6.7% 10.9  0.83  277  3.1% 
C57 Malignant neoplasm of other and unspecified female genital organs     9  0.2% 0.3  0.03  9  0.1% 
C58 Malignant neoplasm of placenta     0  0.0% 0.0 0.00  0  0.0% 
C51-52, 55, 57, 58 Other malignant gynaecological neoplasms     57  1.4% 2.0  0.14  57  0.6% 
C60 Malignant neoplasm of penis 8  0.2% 0.3  0.03      8  0.1% 
C61 Malignant neoplasm of prostate 541  11.5% 24.4  1.01      541  6.1% 
C62 Malignant neoplasm of testis 8  0.2% 0.3  0.03      8  0.1% 
C63 Malignant neoplasm of other and unspecified male genital organs 1  0.0% <0.1 0.00      1  0.0% 
C64 Malignant neoplasm of kidney, except renal pelvis 134  2.9% 6.1  0.44  59  1.4% 2.2  0.17  193  2.2% 
C65 Malignant neoplasm of renal pelvis 1  <0.1% <0.1 0.00  1  0.0% <0.1 <0.01 2  0.0% 
C66 Malignant neoplasm of ureter 4  0.1% 0.2  0.00  5  0.1% 0.2  0.01  9  0.1% 
C67 Malignant neoplasm of bladder 138  2.9% 6.2  0.31  77  1.9% 2.4  0.11  215  2.4% 
C68 Malignant neoplasm of other and unspecified urinary organs 4  0.1% 0.2  0.01  3  0.1% 0.1  <0.01 7  0.1% 
C69 Malignant neoplasm of eye and adnexa 2  <0.1% 0.1  0.01  5  0.1% 0.2  0.01  7  0.1% 
C70 Malignant neoplasm of meninges 1  <0.1% <0.1 <0.01 1  0.0% <0.1 <0.01 2  0.0% 
C71 Malignant neoplasm of brain 160  3.4% 7.1  0.59  110  2.7% 4.5  0.37  270  3.1% 
C72 Malignant neoplasm of spinal cord, cranial nerves and other parts of CNS 0  0.0% 0.0 0.00  1  0.0% <0.1 <0.01 1  0.0% 
C71-72 Malignant neoplasm of brain and spinal cord 160  3.4% 7.1  0.59  111  2.7% 4.5  0.37  271  3.1% 
C73 Malignant neoplasm of thyroid gland 10  0.2% 0.4  0.04  18  0.4% 0.7  0.05  28  0.3% 
C74 Malignant neoplasm of adrenal gland 4  0.1% 0.2  0.01  7  0.2% 0.3  0.02  11  0.1% 
C75 Malignant neoplasm of other endocrine glands and related structures 3  0.1% 0.1  0.01  0  0.0% 0.0  0.00  3  0.0% 
C76 Malignant neoplasm of other and ill-defined sites 19  0.4% 0.8  0.04  18  0.4% 0.6  0.04  37  0.4% 
C80 Malignant neoplasm without specification of site 146  3.1% 6.5  0.40  166  4.0% 5.8  0.37  312  3.5% 
C81 Hodgkin lymphoma 11  0.2% 0.4  0.03  14  0.3% 0.5  0.04  25  0.3% 
C82 Follicular [nodular] non-Hodgkin lymphoma 8  0.2% 0.3  0.01  2  0.0% 0.1  <0.01 10  0.1% 
C83 Diffuse non-Hodgkin lymphoma 30  0.6% 1.3  0.09  12  0.3% 0.5  0.05  42  0.5% 
C84 Peripheral and cutaneous T-cell lymphomas 11  0.2% 0.5  0.04  10  0.2% 0.4  0.04  21  0.2% 
C85 Other and unspecified types of non-Hodgkin lymphoma 97  2.1% 4.3  0.22  104  2.5% 3.8  0.25  201  2.3% 
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 ICD10 cancer site (MORTALITY) MALES FEMALES ALL 
N#: Average annual number of deaths 2011-2012 rounded to nearest integer 
ASR‡: Age standardised rate/100,000 - weighted by ESP of 1976  
Risk†: Cumulative risk of death (%) due to listed cancer up to age 75 years 
N# % of all 
neoplasm 
deaths 
ASR‡ 
ESP 
1976 
Risk† 
75Y 
N# % of all 
neoplasm 
deaths 
ASR‡ 
ESP 
1976 
Risk† 
75Y 
% 
N# % of all 
neoplasm 
deaths 
C82-C85 All non-Hodgkin lymphoma 146  3.1% 6.5  0.37  128  3.1% 4.7  0.34  274  3.1% 
C81-C85 Lymphoma (total) 156  3.3% 6.9  0.40  142  3.4% 5.2  0.38  298  3.4% 
C88 Malignant immunoproliferative diseases 3  0.1% 0.1  0.01  2  0.0% 0.1  0.00  5  0.1% 
C90 Multiple myeloma and malignant plasma cell neoplasms 92  2.0% 4.1  0.26  74  1.8% 2.5  0.14  166  1.9% 
C91 Lymphoid leukaemia 61  1.3% 2.7  0.17  34  0.8% 1.1  0.07  95  1.1% 
C92 Myeloid leukaemia 89  1.9% 3.9  0.20  59  1.4% 2.2  0.14  148  1.7% 
C93 Monocytic leukaemia 1  <0.1% 0.0  <0.01 1  0.0% <0.1 0.00  2  0.0% 
C94 Other leukaemias of specified cell type 1  <0.1% 0.1  <0.01 0  0.0% 0.0  0.00  1  0.0% 
C95 Leukaemia of unspecified cell type 7  0.1% 0.3  0.03  8  0.2% 0.3  0.02  15  0.2% 
C91-95 Leukaemia (total) 158  3.4% 7.0  0.40  101  2.4% 3.6  0.23  259  2.9% 
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue 1  <0.1% <0.1 <0.01 0  0.0% 0.0  0.00  1  0.0% 
C97 Malignant neoplasms of independent (primary) multiple sites 0  0.0% 0.0 0.00  0  0.0% 0.0  0.00  0  0.0% 
D03 Melanoma in situ 0  0.0% 0.0 0.00  0  0.0% 0.0 0.00  0  0.0% 
D04 Carcinoma in situ of skin 0 0.0% 0.0  1  0.0% <0.1 <0.01 1  0.0% 
D32 Benign neoplasm of meninges 3  0.1% 0.2  0.01  7  0.2% 0.2  0.01  10  0.1% 
D33 Benign neoplasm of brain and other parts of CNS 1  0.0% <0.1 0.00  3  0.1% 0.1  0.01  4  0.0% 
D32-D33 Benign neoplasm of meninges, brain & CNS 4  0.1% 0.2  0.01  10  0.2% 0.3  0.02  14  0.2% 
D42 Neoplasm of uncertain or unknown behaviour of meninges 0  0.0% 0.0 0.00  0  0.0% 0.0 0.00  0  0.0% 
D43 Neoplasm of uncertain or unknown behaviour of brain and CNS 16  0.3% 0.7  0.05  13  0.3% 0.4  0.04  29  0.3% 
D42-D43 Neoplasm of uncertain meninges, brain & CNS 16  0.3% 0.7  0.05  13  0.3% 0.4  0.04  29  0.3% 
C71-72, D32-33, D42-43 All malignant, benign, uncertain neoplasms of brain and CNS 179  3.8% 8.0  0.64  133  3.2% 5.3  0.43  312  3.5% 
D45 Polycythaemia vera* 2  0.0% 0.1  <0.01 0  0.0% 0.0 0.00  2  0.0% 
D46 Myelodysplastic syndromes* 43  0.9% 1.9  0.09  27  0.7% 0.8  0.04  70  0.8% 
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue* 17  0.4% 0.7  0.04  16  0.4% 0.4  0.01  33  0.4% 
*Note: For incidence (Appendix I), D45, D46 and part of D47 are included under C96, but mortality statistics presented by the CSO continue to use strict ICD10 codes. 
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APPENDIX III: SUMMARY TABLE -  INCIDENCE TRENDS FOR COMMON CANCERS 
Trends are presented for invasive cancers unless otherwise specified 
APC‡: annual percentage change in rate over period, derived using Joinpoint [6].  Trend†: ↑=significant increase, ↓=significant decrease, ↔=no significant  change, at the 95% level 
 MALES FEMALES 
 *ESP 1976 *ESP 2013 *ESP 1976 *ESP 2013 
 years APC‡ 95%CI trend† years APC‡ 95%CI trend† years APC‡ 95%CI trend† years APC‡ 95%CI trend† 
all invasive, excl. NMSC 1994-2008 1.4 [1.1,1.8] ↑ 1994-2008 1.3 [0.9,1.6] ↑ 1994-2013 1.0 [0.8,1.2] ↑ 1994-2013 0.9 [0.8,1.1] ↑ 
 2008-2013 -0.3 [-1.6,1.1] ↔ 2008-2013 -1.0 [-2.3,0.4] ↔         
                 
all invasive 1994-1999 0.1 [-1.5,1.8] ↔ 1994-2013 1.1 [0.9,1.3] ↑ 1994-2013 1.2 [1.0,1.4] ↑ 1994-2013 1.2 [1.0,1.4] ↑ 
 1999-2013 1.5 [1.2,1.8] ↑             
                 
all registered tumours 1994-1999 0.3 [-1.4,2.0] ↔ 1994-2013 1.5 [1.3,1.7] ↑ 1994-2000 0.5 [-1.4,2.5] ↔ 1994-2000 0.6 [-1.0,2.3] ↔ 
 1999-2013 1.8 [1.6,2.1] ↑     2000-2013 2.5 [2.0,3.0] ↑ 2000-2013 2.3 [1.8,2.7] ↑ 
                 
mouth & pharynx 1994-2001 -4.4 [-6.4,-2.2] ↓ 1994-2001 -4.3 [-6.8,-1.8] ↓ 1994-2013 2.4 [1.4,3.4] ↑ 1994-2013 1.9 [0.8,2.9] ↑ 
 2001-2013 2.8 [1.9,3.7] ↑ 2001-2013 2.4 [1.3,3.4] ↑         
                 
oesophagus 1994-2013 -0.1 [-0.7,0.6] ↔ 1994-2013 0.0 [-0.7,0.7] ↔ 1994-2013 -1.1 [-1.6,-0.5] ↓ 1994-2013 -1.0 [-1.5,-0.4] ↓ 
                 
stomach 1994-2002 -2.9 [-4.5,-1.4] ↓ 1994-2003 -3.1 [-4.5,-1.6] ↓ 1994-2013 -1.5 [-2.0,-1.0] ↓ 1994-2013 -1.5 [-2.0,-1.1] ↓ 
 2002-2013 -0.6 [-1.5,0.3] ↔ 2003-2008 1.0 [-4.0,6.2] ↔         
     2008-2013 -2.2 [-5.5,1.2] ↔         
                 
colorectal 1994-2013 0.1 [-0.2,0.3] ↔ 1994-2008 0.6 [0.2,0.9] ↑ 1994-2013 0.0 [-0.3,0.3] ↔ 1994-2013 0.0 [-0.2,0.3] ↔ 
     2008-2013 -1.0 [-2.5,0.4] ↔         
                 
liver  1994-2013 6.4 [5.4,7.4] ↑ 1994-2013 6.5 [5.5,7.4] ↑ 1994-2013 5.3 [3.6,7.0] ↑ 1994-2013 5.6 [3.9,7.3] ↑ 
                 
pancreas 1994-2013 0.5 [-0.2,1.3] ↔ 1994-2013 0.4 [-0.4,1.1] ↔ 1994-2013 0.4 [-0.3,1.1] ↔ 1994-2013 0.4 [-0.2,1.0] ↔ 
                 
larynx 1994-2013 0.3 [-0.4,1.1] ↔ 1994-2013 0.3 [-0.6,1.3] ↔ 1994-2013 -0.2 [-2.0,1.5] ↔ 1994-2013 -0.5 [-2.2,1.2] ↔ 
                 
lung  1994-2013 -0.8 [-1.0,-0.5] ↓ 1994-2013 -0.5 [-0.7,-0.3] ↓ 1994-2013 2.3 [2.1,2.5] ↑ 1994-2013 2.3 [2.1,2.6] ↑ 
                 
melanoma of skin 1994-2013 4.9 [4.2,5.6] ↑ 1994-2013 5.2 [4.5,5.9] ↑ 1994-2013 2.6 [2.0,3.2] ↑ 1994-2013 2.9 [2.3,3.5] ↑ 
                 
other skin (NMSC) 1994-2001 -1.8 [-2.9,-0.7] ↓ 1994-2001 -1.8 [-2.8,-0.8] ↓ 1994-2000 -0.9 [-2.7,0.9] ↔ 1994-2001 -0.4 [-1.9,1.1] ↔ 
 2001-2013 3.1 [2.7,3.6] ↑ 2001-2013 3.3 [2.9,3.6] ↑ 2000-2013 2.6 [2.1,3.0] ↑ 2001-2013 2.7 [2.1,3.2] ↑ 
                 
breast         1994-2013 1.5 [1.1,1.9] ↑ 1994-2013 1.6 [1.2,1.9] ↑ 
                 
cervix         1994-2013 1.6 [0.5,2.6] ↑ 1994-2013 1.5 [0.4,2.5] ↑ 
                 
corpus uteri         1994-2013 2.5 [1.9,3.0] ↑ 1994-2013 2.7 [2.1,3.2] ↑ 
                 
ovary         1994-2013 -0.8 [-1.4,-0.2] ↓ 1994-2013 -0.5 [-1.0,0.0] ↔ 
                 
prostate 1994-2004 7.8 [6.1,9.6] ↑ 1994-2004 6.3 [4.5,8.2] ↑         
 2004-2013 1.1 [-0.3,2.5] ↔ 2004-2013 0.0 [-1.5,1.4] ↔         
                 
testis 1994-2007 3.8 [2.2,5.5] ↑ 1994-2007 3.8 [2.1,5.5] ↑         
 2007-2013 -1.2 [-5.3,3.1] ↔ 2007-2013 -1.1 [-5.1,3.2] ↔         
 2006-2013 -4.5 [-6.3,-2.7] ↓ 2005-2013 -3.9 [-5.3,-2.4] ↓         
                 
kidney 1994-2013 3.0 [2.4,3.5] ↑ 1994-2013 2.9 [2.2,3.7] ↑ 1994-2013 3.0 [2.4,3.7] ↑ 1994-2008 4.0 [2.9,5.1] ↑ 
             2008-2013 0.4 [-3.7,4.5] ↔ 
                 
bladder 1994-2006 -2.2 [-3.0,-1.4] ↓ 1994-2005 -1.7 [-2.6,-0.8] ↓ 1994-2013 -2.2 [-3.2,-1.3] ↓ 1994-2013 -1.8 [-2.7,-0.8] ↓ 
 2006-2013 -4.5 [-6.3,-2.7] ↓ 2005-2013 -3.9 [-5.3,-2.4] ↓         
                 
brain and CNS (malignant) 1994-2013 -0.3 [-0.9,0.2] ↔ 1994-2013 0.1 [-0.5,0.8] ↔ 1994-2013 0.4 [-0.4,1.1] ↔ 1994-2013 0.5 [-0.3,1.4] ↔ 
                 
thyroid  1994-1999 -6.6 [-20.0,8.9] ↔ 1994-1999 -9.4 [-23.7,7.6] ↔ 1994-2002 3.1 [-3.3,9.9] ↔ 1994-2001 0.6 [-6.3,8.1] ↔ 
 1999-2013 8.7 [6.2,11.3] ↑ 1999-2013 8.6 [5.8,11.5] ↑ 2002-2013 10.9 [8.2,13.7] ↑ 2001-2013 10.4 [8.1,12.7] ↑ 
                 
Hodgkin lymphoma 1994-2013 1.9 [1.1,2.7] ↑ 1994-2013 2.2 [1.4,3.0] ↑ 1994-2013 2.0 [0.6,3.4] ↑ 1994-2013 1.7 [0.3,3.2] ↑ 
                 
non-Hodgkin lymphoma 1994-2013 1.7 [1.2,2.1] ↑ 1994-2013 2.2 [1.7,2.7] ↑ 1994-2013 1.8 [1.2,2.4] ↑ 1994-2013 2.1 [1.5,2.7] ↑ 
                 
myeloma  1994-2013 0.2 [-0.4,0.9] ↔ 1994-2013 0.2 [-0.5,1.0] ↔ 1994-1999 -4.0 [-11.8,4.5] ↔ 1994-2013 -0.3 [-1.4,0.8] ↔ 
         1999-2007 3.6 [-1.4,8.8] ↔     
         2007-2013 -6.0 [-11.5,-0.2] ↓     
                 
leukaemia 1994-2004 3.5 [1.4,5.6] ↑ 1994-2004 3.7 [1.5,6.0] ↑ 1994-2013 -0.1 [-1.0,0.8] ↔ 1994-2008 1.2 [-0.2,2.5] ↔ 
 2004-2013 -3.4 [-5.4,-1.3] ↓ 2004-2013 -3.5 [-5.6,-1.2] ↓     2008-2013 -5.7 [-11.2,0.0] ↔ 
                 
in situ  breast         1994-2013 8.8 [7.4,10.2] ↑ 1994-2013 8.9 [7.4,10.4] ↑ 
                 
in situ  cervix          1994-2013 5.9 [4.6,7.2] ↑ 1994-2013 5.8 [4.5,7.2] ↑ 
*Trends are presented for age-standardised rates calculated using the 1976 European population standard (ESP 1976) and, for comparison, using the 2013 standard (ESP 2013)
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APPENDIX IV: SUMMARY TABLE OF CANCER PREVALENCE: 1994-2013 
 
ICD10 CANCER SITE (PREVALENCE)  20-year prevalence 10-year prevalence 5-year prevalence 3-year prevalence 1-year prevalence 
 diagnosed from Jan 1994 Jan 2004 Jan 2009 Jan 2011 Jan 2013 
   alive 
end 2013  
  
% alive  
 alive 
end 2013  
 
 % alive  
 alive 
end 2013  
 
 % alive  
 alive 
end 2013  
 
 % alive  
 alive 
end 2013  
 
 % alive  
C00 Malignant neoplasm of lip all         275                  50          159                  70            88                  83            61                  88           26                  96  
 female           42                  57            33                  72            23                  92            15                  88             6                  86  
 male         233                  49          126                  70            65                  80            46                  89           20                100  
 <65 years           68                  73            47                  83            29                  85            21                  88             4                  80  
 65+ years         207                  45          112                  66            59                  82            40                  89           22                100  
C01 Malignant neoplasm of base of tongue all         162                  35          135                  48            92                  59            67                  64           25                  81  
 female           43                  41            34                  54            22                  60            17                  65             6                  86  
 male         119                  34          101                  47            70                  58            50                  64           19                  79  
 <65 years           82                  37            74                  52            51                  64            39                  65           16                  84  
 65+ years           80                  34            61                  45            41                  53            28                  64             9                  75  
C02 Malignant neoplasm of other and unspecified parts of tongue all         473                  47          365                  61          248                  69          172                  77           73                  89  
 female         190                  52          153                  64            96                  69            62                  77           29                  88  
 male         283                  45          212                  59          152                  69          110                  77           44                  90  
 <65 years         246                  54          204                  70          143                  77            94                  83           40                  93  
 65+ years         227                  42          161                  53          105                  59            78                  70           33                  85  
C03 Malignant neoplasm of gum all         104                  45            87                  58            62                  66            41                  76           14                  78  
 female           51                  52            43                  65            33                  73            21                  88             5                  83  
 male           53                  40            44                  53            29                  59            20                  67             9                  75  
 <65 years           43                  54            40                  66            31                  67            21                  68             7                  78  
 65+ years           61                  40            47                  53            31                  65            20                  87             7                  78  
C04 Malignant neoplasm of floor of mouth all         190                  37          151                  54          100                  63            75                  73           40                  89  
 female           56                  42            43                  58            27                  63            17                  81             7                  70  
 male         134                  35          108                  52            73                  62            58                  71           33                  94  
 <65 years           92                  41            78                  59            54                  70            42                  84           25                  96  
 65+ years           98                  33            73                  50            46                  55            33                  62           15                  79  
C05 Malignant neoplasm of palate all         132                  44          105                  58            62                  69            40                  77           11                  92  
 female           58                  50            44                  60            25                  78            14                  82             3                100  
 male           74                  40            61                  57            37                  64            26                  74             8                  89  
 <65 years           65                  52            56                  68            37                  76            24                  83             7                  88  
 65+ years           67                  39            49                  50            25                  61            16                  70             4                100  
C06 Malignant neoplasm of other and unspecified parts of mouth all         196                  42          154                  56          104                  67            67                  72           33                  89  
 female           96                  47            76                  59            52                  67            36                  74           19                  95  
 male         100                  38            78                  53            52                  68            31                  71           14                  82  
 <65 years           93                  56            80                  68            60                  80            37                  80           18                  95  
 65+ years         103                  34            74                  47            44                  55            30                  64           15                  83  
C07 Malignant neoplasm of parotid gland all         230                  45          167                  58          105                  70            75                  82           27                  84  
 female         105                  59            72                  73            48                  79            31                  89             8                  89  
 male         125                  37            95                  50            57                  64            44                  77           19                  83  
 <65 years         119                  73            89                  81            61                  88            42                  96           10                100  
 65+ years         111                  32            78                  44            44                  54            33                  69           17                  77  
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ICD10 CANCER SITE (PREVALENCE)  20-year prevalence 10-year prevalence 5-year prevalence 3-year prevalence 1-year prevalence 
 diagnosed from Jan 1994 Jan 2004 Jan 2009 Jan 2011 Jan 2013 
   alive 
end 2013  
  
% alive  
 alive 
end 2013  
 
 % alive  
 alive 
end 2013  
 
 % alive  
 alive 
end 2013  
 
 % alive  
 alive 
end 2013  
 
 % alive  
C08 Malignant neoplasm of other and unspecified major salivary glands all           66                  43            44                  59            24                  59            12                  57             6                  75  
 female           38                  52            24                  67            12                  67              6                  67             2                100  
 male           28                  35            20                  51            12                  52              6                  50             4                  67  
 <65 years           40                  61            26                  70            12                  75              7                  78             3                  75  
 65+ years           26                  30            18                  47            12                  48              5                  42             3                  75  
C09 Malignant neoplasm of tonsil all         306                  49          257                  60          185                  71          131                  81           55                  90  
 female           90                  60            70                  69            48                  74            31                  86           11                  92  
 male         216                  46          187                  57          137                  70          100                  79           44                  90  
 <65 years         216                  56          193                  66          144                  77          102                  82           45                  96  
 65+ years           90                  38            64                  45            41                  56            29                  76           10                  71  
C10 Malignant neoplasm of oropharynx all           67                  29            60                  43            50                  53            44                  62           16                  67  
 female           21                  44            19                  61            15                  71            13                  81             5                  71  
 male           46                  25            41                  38            35                  47            31                  56           11                  65  
 <65 years           38                  31            35                  47            28                  57            23                  68           11                  73  
 65+ years           29                  25            25                  39            22                  48            21                  57             5                  56  
C11 Malignant neoplasm of nasopharynx all         129                  45            87                  55            60                  68            37                  74           14                100  
 female           34                  57            23                  64            15                  65            10                  67             4                100  
 male           95                  42            64                  52            45                  69            27                  77           10                100  
 <65 years           98                  54            70                  63            48                  75            30                  86           12                100  
 65+ years           31                  29            17                  35            12                  50              7                  47             2                100  
C12 Malignant neoplasm of pyriform sinus all         104                  22            89                  36            70                  55            51                  66           20                  91  
 female           18                  21            14                  41            11                  65              7                  78             1                100  
 male           86                  23            75                  36            59                  54            44                  65           19                  91  
 <65 years           44                  22            42                  40            34                  57            25                  69             8                  89  
 65+ years           60                  22            47                  33            36                  54            26                  63           12                  92  
C13 Malignant neoplasm of hypopharynx all           56                  21            46                  29            35                  39            29                  53           13                  72  
 female           22                  21            17                  33            11                  46            10                  71             4                100  
 male           34                  21            29                  27            24                  36            19                  46             9                  64  
 <65 years           25                  28            24                  38            18                  53            17                  68             8                  80  
 65+ years           31                  17            22                  23            17                  30            12                  40             5                  63  
C14 Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx all           59                  22            46                  33            35                  43            28                  56           12                  63  
 female           16                  25            12                  35              8                  36              6                  40             3                  50  
 male           43                  20            34                  32            27                  45            22                  63             9                  69  
 <65 years           32                  26            29                  45            21                  53            19                  63           10                  77  
 65+ years           27                  18            17                  22            14                  33              9                  45             2                  33  
C01-14 Malignant neoplasm of mouth and pharynx all     2,274                  39      1,793                  53      1,232                  63          869                  72        359                  85  
 female         838                  47          644                  60          423                  68          281                  77        107                  86  
 male     1,436                  36      1,149                  49          809                  61          588                  70        252                  84  
 <65 years     1,233                  48      1,040                  62          742                  72          522                  78        220                  90  
 65+ years     1,041                  33          753                  44          490                  53          347                  64        139                  78  
C15 Malignant neoplasm of oesophagus all         999                  15          846                  23          655                  34          510                  44        292                  72  
 female         355                  14          289                  22          213                  32          163                  40           91                  71  
 male         644                  15          557                  23          442                  35          347                  46        201                  73  
 <65 years         326                  18          292                  28          233                  42          179                  54        107                  83  
 65+ years         673                  14          554                  21          422                  31          331                  40        185                  67  
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C16 Malignant neoplasm of stomach all     1,717                  17      1,374                  27      1,009                  38          742                  47        342                  68  
 female         647                  18          492                  26          364                  37          260                  45        128                  70  
 male     1,070                  17          882                  27          645                  38          482                  47        214                  67  
 <65 years         514                  21          440                  33          338                  45          240                  54        120                  72  
 65+ years     1,203                  16          934                  25          671                  35          502                  44        222                  65  
C17 Malignant neoplasm of small intestine all         404                  39          321                  50          237                  64          173                  70           73                  78  
 female         158                  37          127                  48            87                  61            65                  66           24                  80  
 male         246                  40          194                  52          150                  66          108                  74           49                  77  
 <65 years         183                  51          144                  64          106                  78            72                  83           26                  87  
 65+ years         221                  32          177                  42          131                  56          101                  64           47                  73  
C18 Malignant neoplasm of colon all   10,508                  40      7,907                  53      5,126                  64      3,488                  72     1,381                  85  
 female     5,004                  41      3,615                  53      2,335                  65      1,580                  72        599                  82  
 male     5,504                  39      4,292                  52      2,791                  64      1,908                  72        782                  86  
 <65 years     2,536                  47      2,156                  64      1,532                  76      1,092                  83        427                  93  
 65+ years     7,972                  38      5,751                  49      3,594                  60      2,396                  68        954                  81  
C19 Malignant neoplasm of rectosigmoid junction all     1,188                  38          880                  52          536                  62          336                  69        134                  79  
 female         464                  39          328                  50          186                  59          105                  62           39                  66  
 male         724                  38          552                  53          350                  65          231                  72           95                  86  
 <65 years         325                  44          275                  59          188                  72          122                  81           56                  97  
 65+ years         863                  36          605                  49          348                  58          214                  63           78                  70  
C20 Malignant neoplasm of rectum all     4,763                  41      3,567                  56      2,338                  70      1,622                  79        577                  91  
 female     1,769                  44      1,268                  58          799                  71          542                  78        189                  90  
 male     2,994                  40      2,299                  56      1,539                  70      1,080                  80        388                  92  
 <65 years     1,489                  50      1,276                  66          891                  78          634                  86        205                  94  
 65+ years     3,274                  38      2,291                  52      1,447                  66          988                  75        372                  90  
C19-20 Malignant neoplasm of rectosigmoid junction & rectum all     5,951                  40      4,447                  55      2,874                  69      1,958                  77        711                  89  
 female     2,233                  43      1,596                  56          985                  68          647                  75        228                  85  
 male     3,718                  39      2,851                  55      1,889                  69      1,311                  78        483                  90  
 <65 years     1,814                  49      1,551                  65      1,079                  77          756                  85        261                  95  
 65+ years     4,137                  38      2,896                  51      1,795                  64      1,202                  73        450                  86  
C21 Malignant neoplasm of anus and anal canal all         295                  44          239                  59          162                  68          104                  78           42                  88  
 female         175                  46          141                  59            99                  70            61                  81           24                  89  
 male         120                  41            98                  58            63                  65            43                  74           18                  86  
 <65 years         141                  58          116                  70            88                  82            57                  92           23                100  
 65+ years         154                  36          123                  51            74                  57            47                  66           19                  76  
C18-20 Malignant neoplasm of colon & rectum all   16,459                  40    12,354                  54      8,000                  66      5,446                  74     2,092                  86  
 female     7,237                  41      5,211                  54      3,320                  66      2,227                  73        827                  83  
 male     9,222                  39      7,143                  53      4,680                  66      3,219                  75     1,265                  88  
 <65 years     4,350                  48      3,707                  64      2,611                  76      1,848                  84        688                  93  
 65+ years   12,109                  38      8,647                  50      5,389                  62      3,598                  69     1,404                  83  
C18-21 Malignant neoplasm of colon, rrectum & anus all   16,754                  40    12,593                  54      8,162                  66      5,550                  74     2,134                  86  
 female     7,412                  41      5,352                  54      3,419                  66      2,288                  73        851                  83  
 male     9,342                  39      7,241                  53      4,743                  66      3,262                  75     1,283                  88  
 <65 years     4,491                  48      3,823                  64      2,699                  76      1,905                  84        711                  94  
 65+ years   12,263                  38      8,770                  50      5,463                  62      3,645                  69     1,423                  83  
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C22 Malignant neoplasm of liver and intrahepatic bile ducts all         430                  16          387                  20          321                  29          263                  36        130                  51  
 female         127                  14          108                  17            89                  26            79                  35           34                  50  
 male         303                  17          279                  22          232                  30          184                  37           96                  51  
 <65 years         203                  23          181                  29          148                  38          123                  49           60                  65  
 65+ years         227                  12          206                  16          173                  23          140                  29           70                  43  
C23 Malignant neoplasm of gallbladder all           92                  10            78                  16            60                  24            50                  29           34                  53  
 female           68                  10            56                  15            43                  24            35                  29           25                  53  
 male           24                     9            22                  16            17                  23            15                  31             9                  53  
 <65 years           28                  14            28                  22            20                  36            14                  44             7                  78  
 65+ years           64                     9            50                  13            40                  21            36                  26           27                  49  
C24 Malignant neoplasm of other and unspecified parts of biliary tract all         251                  15          204                  22          158                  30          128                  39           78                  62  
 female         107                  13            83                  19            64                  26            52                  33           32                  53  
 male         144                  17          121                  25            94                  35            76                  46           46                  70  
 <65 years           70                  21            60                  31            49                  44            43                  61           28                  82  
 65+ years         181                  14          144                  20          109                  27            85                  33           50                  54  
C25 Malignant neoplasm of pancreas all         589                     7          509                  11          422                  17          353                  24        215                  43  
 female         293                     7          239                  11          193                  17          163                  23           99                  42  
 male         296                     7          270                  11          229                  18          190                  25        116                  44  
 <65 years         214                  11          194                  16          161                  25          133                  34           82                  59  
 65+ years         375                     6          315                     9          261                  15          220                  20        133                  37  
C26 Malignant neoplasm of other and ill-defined digestive organs all           34                     4            27                     8            22                  13            18                  18           11                  31  
 female           21                     5            15                     8            13                  14            10                  18             6                  27  
 male           13                     4            12                     7              9                  12              8                  19             5                  39  
 <65 years           14                  10            11                  15            10                  24            10                  37             5                  56  
 65+ years           20                     3            16                     6            12                     9              8                  11             6                  23  
C30 Malignant neoplasm of nasal cavity and middle ear all           93                  45            70                  59            48                  72            29                  83           10                100  
 female           47                  48            37                  67            25                  74            16                  89             6                100  
 male           46                  43            33                  52            23                  70            13                  77             4                100  
 <65 years           46                  60            37                  70            27                  84            16                  94             7                100  
 65+ years           47                  37            33                  50            21                  60            13                  72             3                100  
C31 Malignant neoplasm of accessory sinuses all           62                  26            44                  39            26                  50            18                  58             6                  60  
 female           29                  32            19                  50            10                  59            10                  71             3                  75  
 male           33                  23            25                  33            16                  46              8                  47             3                  50  
 <65 years           33                  36            26                  52            17                  65            10                  71             2                  50  
 65+ years           29                  20            18                  29              9                  35              8                  47             4                  67  
C32 Malignant neoplasm of larynx all     1,155                  43          873                  58          564                  70          389                  78        153                  89  
 female         178                  43          138                  64            89                  75            62                  78           31                  91  
 male         977                  43          735                  57          475                  69          327                  78        122                  88  
 <65 years         428                  47          363                  61          258                  72          178                  77           54                  87  
 65+ years         727                  41          510                  56          306                  69          211                  78           99                  90  
C33 Malignant neoplasm of trachea all             4                     7              3                  18              3                  30              2                  33             1                100  
 female             1                     4              1                  13              1                  20             -                   -   
 male             3                  11              2                  22              2                  40              2                  50             1                100  
 <65 years             1                     6              1                  17              1                  25              1                  33             1                100  
 65+ years             3                     8              2                  18              2                  33              1                  33    
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C34 Malignant neoplasm of bronchus and lung all     4,508                  12      3,929                  19      3,187                  28      2,590                  37     1,388                  59  
 female     2,298                  16      2,028                  23      1,644                  34      1,353                  44        711                  66  
 male     2,210                  10      1,901                  16      1,543                  24      1,237                  32        677                  54  
 <65 years     1,392                  14      1,269                  22      1,062                  35          857                  45        466                  72  
 65+ years     3,116                  11      2,660                  18      2,125                  26      1,733                  34        922                  55  
C33-34 Malignant neoplasm of bronchus, lung or trachea all     4,512                  12      3,932                  19      3,190                  28      2,592                  37     1,389                  59  
 female     2,299                  16      2,029                  23      1,645                  34      1,353                  44        711                  66  
 male     2,213                  10      1,903                  16      1,545                  24      1,239                  32        678                  54  
 <65 years     1,393                  14      1,270                  22      1,063                  35          858                  45        467                  72  
 65+ years     3,119                  11      2,662                  18      2,127                  26      1,734                  34        922                  55  
C37 Malignant neoplasm of thymus all           63                  50            52                  69            38                  88            28                  97           11                  92  
 female           26                  52            23                  77            19                  91            15                100             7                100  
 male           37                  49            29                  64            19                  86            13                  93             4                  80  
 <65 years           32                  58            26                  84            19                  86            13                100             5                100  
 65+ years           31                  44            26                  59            19                  91            15                  94             6                  86  
C38 Malignant neoplasm of heart, mediastinum and pleura all           37                  15            27                  22            19                  30            14                  36             7                  78  
 female             8                  10              6                  15              3                  15              3                  30             1                100  
 male           29                  17            21                  25            16                  37            11                  38             6                  75  
 <65 years           29                  29            21                  38            16                  53            12                  55             6                  86  
 65+ years             8                     5              6                     9              3                     9              2                  12             1                  50  
C40 Malignant neoplasm of bone and articular cartilage of limbs all         225                  58          133                  70            79                  79            53                  79           22                100  
 female           90                  61            51                  74            30                  86            21                  81             7                100  
 male         135                  57            82                  67            49                  75            32                  78           15                100  
 <65 years         188                  66          109                  78            69                  87            45                  87           18                100  
 65+ years           37                  37            24                  46            10                  48              8                  53             4                100  
C41 Malignant neoplasm of bone and articular cartilage of other and unspecified sites all         129                  42            84                  52            51                  59            35                  65           12                  71  
 female           56                  41            36                  48            19                  61            13                  65             6                  86  
 male           73                  42            48                  56            32                  58            22                  65             6                  60  
 <65 years           96                  49            63                  56            38                  61            25                  68             9                  82  
 65+ years           33                  29            21                  44            13                  54            10                  59             3                  50  
C43 Malignant melanoma of skin all     8,510                  71      6,097                  80      3,832                  87      2,501                  91        954                  97  
 female     5,230                  76      3,565                  84      2,196                  90      1,373                  93        497                  98  
 male     3,280                  65      2,532                  75      1,636                  83      1,128                  89        457                  96  
 <65 years     4,458                  83      3,277                  89      2,057                  94      1,314                  96        494                  99  
 65+ years     4,052                  62      2,820                  71      1,775                  80      1,187                  87        460                  95  
C44 Other malignant neoplasms of skin (non-melanoma skin cancers [NMSC]) all   91,823                  69    66,113                  83    41,157                  91    27,055                  95     9,636                  98  
 female   43,202                  72    30,339                  85    18,489                  92    12,093                  96     4,236                  99  
 male   48,621                  68    35,774                  82    22,668                  90    14,962                  94     5,400                  98  
 <65 years   24,416                  94    19,564                  97    12,925                  99      8,641                  99     3,093                100  
 65+ years   67,407                  63    46,549                  79    28,232                  88    18,414                  93     6,543                  98  
C45 Mesothelioma all           53                  10            46                  13            44                  22            37                  29           26                  63  
 female             9                  11              9                  16              9                  30              7                  39             2                  50  
 male           44                  10            37                  12            35                  20            30                  27           24                  65  
 <65 years           22                  11            20                  20            18                  38            14                  48             9                  90  
 65+ years           31                     9            26                  10            26                  17            23                  23           17                  55  
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C46 Kaposi sarcoma all           70                  59            53                  75            32                  80            28                  85             6                100  
 female             7                  58              6                  67              3                100              2                100    
 male           63                  59            47                  76            29                  78            26                  84             6                100  
 <65 years           58                  60            45                  75            28                  80            25                  83             5                100  
 65+ years           12                  57              8                  73              4                  80              3                100             1                100  
C47 Malignant neoplasm of peripheral nerves and autonomic nervous system all           68                  47            39                  56            16                  70            11                  73             3                100  
 female           31                  42            18                  47              6                  50              3                  50             1                100  
 male           37                  51            21                  66            10                  91              8                  89             2                100  
 <65 years           59                  54            38                  66            16                  80            11                  92             3                100  
 65+ years             9                  24              1                     8             -                   -            -                   -   
C48 Malignant neoplasm of retroperitoneum and peritoneum all           97                  29            79                  38            59                  53            46                  58           24                  80  
 female           60                  26            49                  31            40                  48            32                  53           17                  81  
 male           37                  36            30                  60            19                  68            14                  70             7                  78  
 <65 years           50                  39            41                  52            26                  74            18                  82           11                100  
 65+ years           47                  23            38                  30            33                  43            28                  48           13                  68  
C49 Malignant neoplasm of other connective and soft tissue all         838                  47          572                  58          343                  65          231                  72        103                  84  
 female         364                  50          248                  60          135                  63            93                  72           40                  80  
 male         474                  45          324                  57          208                  65          138                  72           63                  88  
 <65 years         483                  57          326                  67          198                  73          133                  79           53                  86  
 65+ years         355                  38          246                  49          145                  55            98                  64           50                  83  
C50 Malignant neoplasm of breast all   29,828                  67    21,230                  81    12,720                  89      8,097                  93     2,882                  97  
 female   29,622                  67    21,058                  81    12,597                  89      8,004                  93     2,844                  97  
 male         206                  57          172                  73          123                  85            93                  91           38                  93  
 <65 years   15,741                  76    12,501                  89      7,913                  95      5,099                  97     1,810                  99  
 65+ years   14,087                  59      8,729                  71      4,807                  81      2,998                  86     1,072                  93  
C51 Malignant neoplasm of vulva all         390                  48          291                  62          179                  74          117                  80           38                  91  
 <65 years         164                  71          133                  83            84                  91            57                  95           18                100  
 65+ years         226                  39          158                  51            95                  63            60                  69           20                  83  
C52 Malignant neoplasm of vagina all           65                  32            47                  40            31                  53            25                  61           11                  65  
 <65 years           22                  35            15                  43            12                  60              8                  67             1                100  
 65+ years           43                  30            32                  39            19                  50            17                  59           10                  63  
C53 Malignant neoplasm of cervix uteri all     2,977                  64      2,044                  73      1,259                  80          765                  86        257                  95  
 <65 years     2,509                  70      1,802                  78      1,111                  85          666                  90        213                  98  
 65+ years         468                  44          242                  47          148                  56            99                  69           44                  80  
C54 Malignant neoplasm of corpus uteri all     3,873                  64      2,735                  74      1,740                  82      1,130                  87        409                  94  
 <65 years     1,497                  76      1,254                  84          855                  89          579                  93        219                  98  
 65+ years     2,376                  59      1,481                  68          885                  77          551                  81        190                  89  
C55 Malignant neoplasm of uterus, part unspecified all         157                  38          108                  49            67                  55            40                  62           11                  65  
 <65 years           70                  50            53                  65            38                  75            26                  87             6                  86  
 65+ years           87                  33            55                  40            29                  41            14                  40             5                  50  
C56 Malignant neoplasm of ovary all     2,027                  31      1,418                  41          942                  53          678                  63        250                  72  
 <65 years     1,146                  41          857                  56          578                  70          416                  80        150                  93  
 65+ years         881                  24          561                  29          364                  38          262                  47        100                  54  
C57 Malignant neoplasm of other and unspecified female genital organs all           66                  38            53                  45            35                  47            25                  56           10                  71  
 <65 years           35                  49            33                  64            23                  64            19                  70             7                  88  
 65+ years           31                  31            20                  31            12                  31              6                  33             3                  50  
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C58 Malignant neoplasm of placenta all           24                  92            17                  94            14                100              9                100             3                100  
 <65 years           24                  92            17                  94            14                100              9                100             3                100  
 65+ years 0 0 0 0 0 0 0 0 0 0 
C51-52, 55, 57, 58 Other malignant neoplasms: gynaecological all         702                  43          516                  55          326                  64          216                  70           73                  79  
 <65 years         315                  59          251                  73          171                  80          119                  86           35                  95  
 65+ years         387                  35          265                  44          155                  52            97                  57           38                  68  
C60 Malignant neoplasm of penis all         245                  51          175                  66          116                  77            82                  83           32                  97  
 <65 years         104                  67            81                  78            58                  87            37                  86           14                  93  
 65+ years         141                  44            94                  59            58                  70            45                  80           18                100  
C61 Malignant neoplasm of prostate all   28,431                  63    23,952                  80    14,868                  89      9,540                  94     3,140                  98  
 <65 years     6,563                  86      6,341                  93      4,898                  97      3,438                  98     1,296                100  
 65+ years   21,868                  58    17,611                  76      9,970                  86      6,102                  91     1,844                  96  
C62 Malignant neoplasm of testis all     2,575                  94      1,616                  97          829                  97          487                  97        153                  99  
 <65 years     2,492                  94      1,584                  97          815                  97          478                  98        150                  99  
 65+ years           83                  76            32                  80            14                  78              9                  82             3                100  
C63 Malignant neoplasm of other and unspecified male genital organs all           29                  55            18                  72            15                  88            10                  91             3                100  
 <65 years           10                  77              7                100              5                100              4                100             2                100  
 65+ years           19                  48            11                  61            10                  83              6                  86             1                100  
C64 Malignant neoplasm of kidney, except renal pelvis all     3,575                  46      2,792                  58      1,869                  68      1,274                  75        476                  83  
 female     1,359                  49      1,034                  59          662                  69          440                  75        161                  83  
 male     2,216                  45      1,758                  57      1,207                  68          834                  75        315                  84  
 <65 years     1,646                  59      1,357                  70          946                  79          669                  85        254                  93  
 65+ years     1,929                  39      1,435                  49          923                  60          605                  66        222                  75  
C65 Malignant neoplasm of renal pelvis all         111                  41            93                  53            74                  67            53                  71           25                  93  
 female           45                  50            39                  63            30                  77            19                  79             7                100  
 male           66                  37            54                  47            44                  61            34                  67           18                  90  
 <65 years           30                  54            26                  67            19                  76            14                  82             7                  88  
 65+ years           81                  38            67                  49            55                  64            39                  67           18                  95  
C66 Malignant neoplasm of ureter all         107                  40            77                  49            60                  62            43                  74           18                  90  
 female           39                  40            25                  42            20                  56            12                  67             4                  80  
 male           68                  40            52                  54            40                  66            31                  78           14                  93  
 <65 years           30                  58            22                  73            20                  77            11                  92             6                100  
 65+ years           77                  36            55                  44            40                  56            32                  70           12                  86  
C67 Malignant neoplasm of bladder all     3,654                  40      2,299                  51      1,321                  60          879                  67        332                  79  
 female     1,100                  41          662                  49          369                  55          257                  64        104                  78  
 male     2,554                  39      1,637                  52          952                  62          622                  68        228                  80  
 <65 years         808                  59          567                  68          320                  74          213                  79           80                  88  
 65+ years     2,846                  36      1,732                  47      1,001                  56          666                  63        252                  77  
C68 Malignant neoplasm of other and unspecified urinary organs all           33                  32            21                  44            13                  59            11                  79             4                100  
 female           11                  28              9                  45              5                  50              4                  80             2                100  
 male           22                  35            12                  43              8                  67              7                  78             2                100  
 <65 years             7                  39              4                  44              3                100              3                100             2                100  
 65+ years           26                  31            17                  44            10                  53              8                  73             2                100  
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C69 Malignant neoplasm of eye and adnexa all         556                  60          372                  75          224                  84          162                  91           56                  95  
 female         257                  58          161                  73          100                  84            70                  89           19                  95  
 male         299                  62          211                  77          124                  84            92                  92           37                  95  
 <65 years         285                  76          200                  83          133                  91            91                  95           33                  97  
 65+ years         271                  50          172                  68            91                  77            71                  86           23                  92  
C70 Malignant neoplasm of meninges all           80                  47            63                  61            43                  72            22                  73             9                  82  
 female           49                  45            38                  59            24                  69            12                  71             5                  71  
 male           31                  50            25                  66            19                  76            10                  77             4                100  
 <65 years           31                  71            27                  87            18                  86            10                  83             5                100  
 65+ years           49                  39            36                  50            25                  64            12                  67             4                  67  
C71 Malignant neoplasm of brain all     1,167                  20          832                  26          590                  36          443                  43        219                  66  
 female         540                  22          382                  28          280                  39          199                  45        101                  66  
 male         627                  19          450                  25          310                  34          244                  42        118                  66  
 <65 years         966                  29          687                  38          473                  51          344                  60        155                  82  
 65+ years         201                     8          145                  11          117                  17            99                  22           64                  44  
C72 Malignant neoplasm of spinal cord, cranial nerves and other parts of CNS all         130                  60            77                  67            54                  82            34                  81           13                  87  
 female           74                  66            45                  71            32                  80            18                  82             8                  80  
 male           56                  53            32                  62            22                  85            16                  80             5                100  
 <65 years         114                  70            70                  80            47                  92            30                  88           13                100  
 65+ years           16                  29              7                  26              7                  47              4                  50            -                   - 
C71-72 Malignant neoplasm of brain and CNS all     1,297                  22          909                  28          644                  38          477                  45        232                  67  
 female         614                  24          427                  30          312                  41          217                  46        109                  67  
 male         683                  20          482                  26          332                  35          260                  44        123                  67  
 <65 years     1,080                  31          757                  40          520                  53          374                  61        168                  84  
 65+ years         217                     9          152                  11          124                  17          103                  23           64                  44  
C73 Malignant neoplasm of thyroid gland all     2,031                  79      1,621                  87      1,093                  90          758                  92        280                  92  
 female     1,557                  83      1,233                  89          827                  92          574                  93        197                  92  
 male         474                  68          388                  79          266                  84          184                  89           83                  93  
 <65 years     1,575                  92      1,277                  95          872                  96          611                  97        227                  97  
 65+ years         456                  53          344                  66          221                  73          147                  76           53                  75  
C74 Malignant neoplasm of adrenal gland all         129                  49            82                  59            57                  65            37                  74           15                  94  
 female           63                  45            40                  55            26                  61            19                  83           11                  92  
 male           66                  52            42                  63            31                  69            18                  67             4                100  
 <65 years         107                  55            68                  64            48                  70            30                  83           12                100  
 65+ years           22                  31            14                  41              9                  47              7                  50             3                  75  
C75 Malignant neoplasm of other endocrine glands and related structures all         133                  62            89                  72            50                  78            39                  95           12                  92  
 female           64                  63            45                  74            21                  81            17                  94             7                100  
 male           69                  60            44                  70            29                  76            22                  96             5                  83  
 <65 years           89                  70            59                  84            37                  84            28                  97             8                  89  
 65+ years           44                  50            30                  56            13                  65            11                  92             4                100  
C76 Malignant neoplasm of other and ill-defined sites all           88                  13            52                  21            29                  29            25                  39           10                  59  
 female           59                  14            35                  21            20                  30            17                  39             8                  57  
 male           29                  12            17                  19              9                  27              8                  38             2                  67  
 <65 years           53                  33            31                  48            14                  52            12                  60             5                100  
 65+ years           35                     7            21                  11            15                  21            13                  29             5                  42  
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C77 Secondary and unspecified malignant neoplasm of lymph nodes all             8                  29              6                  33              6                  55              6                  67             3                  75  
 female             3                  20              1                  11              1                  20              1                  33             1                100  
 male             5                  39              5                  56              5                  83              5                  83             2                  67  
 <65 years             6                  55              4                  67              4                100              4                100             3                100  
 65+ years             2                  12              2                  17              2                  29              2                  40            -                   - 
C80 Malignant neoplasm without specification of site all         693                     6          473                  10          356                  16          268                  20        164                  35  
 female         314                     5          205                     9          155                  13          117                  17           68                  32  
 male         379                     7          268                  12          201                  19          151                  24           96                  38  
 <65 years         232                     9          186                  18          143                  28          105                  33           59                  49  
 65+ years         461                     5          287                     8          213                  12          163                  16        105                  31  
C81 Hodgkin lymphoma all     1,605                  77      1,012                  83          600                  87          355                  88        118                  89  
 female         733                  78          457                  84          273                  87          157                  87           50                  91  
 male         872                  76          555                  83          327                  87          198                  88           68                  87  
 <65 years     1,407                  87          872                  91          524                  94          312                  95        106                  94  
 65+ years         198                  44          140                  54            76                  59            43                  57           12                  60  
C82 Follicular [nodular] non-Hodgkin lymphoma all     1,516                  73      1,227                  82          784                  90          515                  94        174                  94  
 female         799                  74          648                  83          417                  90          284                  93        108                  95  
 male         717                  72          579                  82          367                  90          231                  94           66                  92  
 <65 years         800                  82          668                  91          435                  96          288                  98        106                  97  
 65+ years         716                  65          559                  74          349                  84          227                  88           68                  88  
C83 Diffuse non-Hodgkin lymphoma all     2,116                  50      1,695                  60      1,122                  68          763                  72        295                  85  
 female         919                  51          721                  60          475                  67          318                  72        125                  83  
 male     1,197                  50          974                  60          647                  69          445                  73        170                  86  
 <65 years         978                  63          784                  73          510                  80          348                  83        132                  92  
 65+ years     1,138                  43          911                  52          612                  60          415                  65        163                  80  
C84 Peripheral and cutaneous T-cell lymphomas all         461                  56          315                  61          196                  66          125                  68           49                  80  
 female         192                  58          119                  59            74                  66            49                  66           21                  75  
 male         269                  55          196                  61          122                  66            76                  69           28                  85  
 <65 years         253                  68          175                  73          110                  79            69                  82           25                  86  
 65+ years         208                  47          140                  50            86                  54            56                  56           24                  75  
C85 Other and unspecified types of non-Hodgkin lymphoma all     1,476                  38          895                  52          492                  61          331                  69        152                  79  
 female         743                  40          449                  54          244                  63          159                  68           73                  77  
 male         733                  36          446                  50          248                  59          172                  69           79                  81  
 <65 years         629                  49          372                  67          204                  76          140                  86           57                  93  
 65+ years         847                  32          523                  45          288                  53          191                  60           95                  73  
C82-85 All non-Hodgkin lymphoma all     5,569                  51      4,132                  63      2,594                  72      1,734                  76        670                  85  
 female     2,653                  52      1,937                  64      1,210                  72          810                  77        327                  85  
 male     2,916                  49      2,195                  62      1,384                  71          924                  76        343                  86  
 <65 years     2,660                  64      1,999                  77      1,259                  84          845                  88        320                  94  
 65+ years     2,909                  43      2,133                  54      1,335                  63          889                  68        350                  79  
C81-85 Lymphoma (total) all     7,174                  55      5,144                  66      3,194                  74      2,089                  78        788                  86  
 female     3,386                  56      2,394                  67      1,483                  75          967                  78        377                  85  
 male     3,788                  54      2,750                  65      1,711                  73      1,122                  78        411                  86  
 <65 years     4,067                  70      2,871                  81      1,783                  87      1,157                  90        426                  94  
 65+ years     3,107                  43      2,273                  54      1,411                  62          932                  67        362                  78  
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C88 Malignant immunoproliferative diseases all         136                  48          117                  66            78                  85            50                  88           15                  94  
 female           56                  51            42                  64            27                  79            16                  76             7                  88  
 male           80                  46            75                  68            51                  88            34                  94             8                100  
 <65 years           32                  80            30                  86            19                  95            12                  92             2                100  
 65+ years         104                  43            87                  61            59                  82            38                  86           13                  93  
C90 Multiple myeloma and malignant plasma cell neoplasms all     1,253                  29      1,097                  45          776                  61          540                  72        220                  86  
 female         513                  27          453                  44          298                  58          194                  67           74                  83  
 male         740                  30          644                  46          478                  63          346                  75        146                  87  
 <65 years         447                  42          395                  65          283                  80          198                  88           75                  93  
 65+ years         806                  24          702                  39          493                  54          342                  65        145                  83  
C91 Lymphoid leukaemia all     2,731                  54      2,007                  70      1,139                  81          675                  86        174                  91  
 female     1,063                  55          743                  71          439                  83          252                  85           68                  92  
 male     1,668                  53      1,264                  70          700                  80          423                  86        106                  90  
 <65 years     1,274                  73          921                  86          561                  91          339                  93           94                  93  
 65+ years     1,457                  44      1,086                  61          578                  73          336                  79           80                  88  
C92 Myeloid leukaemia all         933                  32          667                  39          418                  46          268                  51        103                  68  
 female         435                  35          313                  42          194                  50          126                  56           48                  69  
 male         498                  30          354                  37          224                  43          142                  47           55                  67  
 <65 years         623                  49          434                  60          260                  66          160                  71           56                  93  
 65+ years         310                  19          233                  24          158                  31          108                  36           47                  51  
C93 Monocytic leukaemia all           15                  23            11                  28              8                  47              5                  46             4                  80  
 female             8                  33              5                  29              4                  36              2                  33             1                100  
 male             7                  17              6                  27              4                  67              3                  60             3                  75  
 <65 years           13                  45              9                  53              7                  64              4                  57             3                  75  
 65+ years             2                     5              2                     9              1                  17              1                  25             1                100  
C94 Other leukaemias of specified cell type all           52                  24            40                  40            27                  69            18                  78             7                100  
 female           20                  25            15                  42              8                  73              4                  67             3                100  
 male           32                  23            25                  39            19                  68            14                  82             4                100  
 <65 years           27                  41            22                  58            14                  74              7                  88             1                100  
 65+ years           25                  16            18                  29            13                  65            11                  73             6                100  
C95 Leukaemia of unspecified cell type all           80                  10            45                  15            21                  15            18                  21           11                  31  
 female           37                  10            23                  16            11                  18            10                  26             7                  54  
 male           43                  10            22                  13            10                  13              8                  16             4                  18  
 <65 years           46                  30            29                  40            13                  41            12                  55             8                  67  
 65+ years           34                     5            16                     7              8                     7              6                     9             3                  13  
C91-95 Leukaemia (total) all     3,811                  42      2,770                  55      1,613                  64          984                  69        299                  77  
 female     1,563                  43      1,099                  56          656                  66          394                  69        127                  79  
 male     2,248                  42      1,671                  55          957                  63          590                  68        172                  75  
 <65 years     1,983                  61      1,415                  73          855                  80          522                  83        162                  91  
 65+ years     1,828                  32      1,355                  44          758                  53          462                  57        137                  64  
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue all     2,128                  44      1,658                  56      1,044                  70          688                  76        228                  84  
 female         983                  46          733                  59          433                  71          267                  75           92                  86  
 male     1,145                  42          925                  55          611                  69          421                  77        136                  83  
 <65 years         753                  75          566                  83          335                  87          220                  90           83                  94  
 65+ years     1,375                  36      1,092                  49          709                  64          468                  71        145                  80  
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D32-33 Benign brain & CNS all     1,974                  74      1,231                  80          737                  88          470                  90        140                  91  
 female     1,362                  74          870                  80          519                  89          324                  90           89                  94  
 male         612                  74          361                  80          218                  86          146                  89           51                  86  
 <65 years     1,086                  91          703                  95          434                  98          282                  99           81                  99  
 65+ years         888                  60          528                  67          303                  77          188                  79           59                  82  
D42-43 Neoplasm of uncertain meninges, brain & CNS all         604                  84          433                  87          292                  90          184                  92           65                  96  
 female         289                  83          220                  87          151                  90            96                  91           30                  91  
 male         315                  85          213                  88          141                  91            88                  92           35                100  
 <65 years         517                  89          365                  93          243                  96          152                  97           55                100  
 65+ years           87                  61            68                  66            49                  70            32                  73           10                  77  
C71-72, D32-33, D42-43 Malignant, benign or uncertain neoplasms of the brain and CNS all     3,875                  41      2,573                  48      1,673                  58      1,131                  63        437                  77  
 female     2,265                  48      1,517                  55          982                  65          637                  68        228                  78  
 male     1,610                  35      1,056                  41          691                  51          494                  58        209                  76  
 <65 years     2,683                  51      1,825                  60      1,197                  71          808                  77        304                  90  
 65+ years     1,192                  29          748                  33          476                  40          323                  44        133                  58  
 
 
 
